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ABSTRACT 
 
To be male or female, that is the question. In Drosophila melanogaster, all aspects of 
somatic sex determination are under the control of the binary switch gene, Sex lethal (Sxl). 
The primary determinant of the activity state of Sxl is the number of X-chromosomes.  XX 
embryos develop as females, while XY embryos develop as males. Sxl is stably expressed 
in females via autoregulatory mRNA splicing that occurs as a consequence of a brief pulse 
of transcription from establishment promoter SxlPe. Female-specific expression of SxlPe 
requires a two X chromosome dose of the X-signal elements sisA, sc, upd and runt.  Males 
fail to express SxlPe as they carry a single dose of the X-signal elements (XSEs). 
 
Understanding regulation of SxlPe demanded an advanced quantification tool to monitor 
Sxl activity in vivo. The Sxl transgene system thus developed enables the monitoring of 
endogenous Sxl activity, both as nascent transcripts and as mature mRNA. The key feature 
is that intron sequences are swapped between related species to allow allele-specific 
detection, by in situ hybridization, of expression from mutant and wild type transgenes 
side-by-side in every nucleus of the embryo. The transgene system is fully functional and 
helps exploit classical Drosophila genetics to monitor the biological effects of engineered 
Sxl mutations. Using this powerful system, I have characterized the cis interactions of the 
X-signal elements Sc/Da, repressor Dpn and also defined the regulatory regions of SxlPe, 
to discover the means by which this sensitive promoter switch operates. 
 
 iii 
 
In defining the different regulatory units our results validated the previous findings of 
Estes et al., using SxlPe lacZ fusions. The 3.0kb enhancer is indeed an equivalent of the 
full length endogenous SxlPe enhancer and drives a robust, wild type expression. In 
addition, studying the promoter deletions in context of full length Sxl transgenes 
confirmed that the minimal, 400bp enhancer that drove low lacZ expression in Estes et al., 
does activate SxlPe and is both necessary and sufficient for SxlPe activation. 
 
In studying how binding site interactions impacted SxlPe regulation, my findings revealed 
that the loss of the single canonical E-box, Sc/Da 3 turned the SxlPe switch off, killing 
females. This not only led to the discovery of a prominent regulatory site critical for 
female-specific regulation but also challenged the previous notion that multiple Sc/Da are 
responsible for proper operation of SxlPe switch. Additionally, Sc/Da 3 proved that 
canonical E-box sites are important or even more so to SxlPe regulation, compared to the 
non-canonical sites.  
 
Mutating repressor Dpn binding sites triggered ectopic SxlPe expression in males and 
subsequently male lethality. The non-canonical site 3 had the strongest effect on SxlPe 
regulation than the canonical Dpn sites 1 and 2. The surprising finding is that Dpn binding 
site mutation is not only capable of initiating SxlPe expression from the mutant bearing 
transgene, but also activating the wild-type Sxl from the control transgene in trans. This 
phenomenon suggests that transactivation might be a novel approach for the fly to amplify 
X dose signal and ensure female specificity.  
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CHAPTER I 
INTRODUCTION 
 
Cell fates are established through an intricate cascade of regulatory pathways, often 
triggered by small quantitative differences in transcription factors or signaling molecules. 
How the quantitative difference is interpreted at a molecular level by enhancers or cis 
regulatory modules to give rise to complex and precise pattern of gene expression in a 
specific spatiotemporal manner has been an intensively investigated field for the past few 
decades.  Some well-studied examples in Drosophila include how changes in levels of 
Bicoid and Dorsal, two maternally deposited transcription factors, establish distinct gene 
expression patterns and specify anterior-posterior and dorsal-ventral axes of the embryo 
[1-4].  
 
Drosophila somatic sex determination is another classical model of how cell fate 
commitment relies on subtle differences of regulatory protein concentrations. The X 
chromosome dose is conveyed to the master regulatory gene, Sxl-lethal (Sxl) by four X-
linked signaling elements (XSEs) [5-7]. The two-fold difference is sensed by the 
establishment promoter, SxlPe and the subsequent activity of Sxl controls the sexual 
development via a cascade of regulatory events [5, 7, 8]. In XX embryos, Sxl is activated 
by SxlPe, which results in female differentiation and development. In XY embryos, Sxl 
remains OFF as one dose of XSE proteins is not enough to activate SxlPe. Consequently, 
dosage compensation and male development take place [7].  SxlPe converts the X dose 
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signal to an all or none response, in order to establish the opposite sexual identities. 
Therefore, deciphering the nature of dose-sensitive SxlPe and its regulation mechanism is 
of great importance and can greatly enhance our understanding of transcriptional 
regulation, cell fate decisions and embryonic development.  
 
The establishment and maintenance of Sxl  
Somatic sex determination in Drosophila melanogaster occurs as a result of Sxl regulation 
by a dual phase process – establishment and maintenance. The phases are governed by 
two distinct promoters; an early acting, establishment promoter SxlPe and the late acting, 
maintenance promoter SxlPm.  
 
 
 
Fig. 1.1: Establishment of SXL autoregulatory loop 
(Left Panel) In XX females, SxlPe is activated in response to the collective level of four XSEs. 
SxlPe activation provides the initial burst of SXL protein, which is then used to process the pre-
mRNA from SxlPm to maintain the production of functional SXL. The autoregulatory splicing 
loop allows Sxl to be locked into the “ON” state in females. (Right Panel) In XY males, SxlPe 
remains inactive and the pre-mRNA from SxlPm is spliced into a male default form, which 
contains translation termination signal in the third exon. As a result, no functional SXL is produced 
in males. 
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SxlPe, one of the earliest developmental targets of Drosophila is activated during a small 
developmental window, the syncytial blastoderm stages by a transcriptional response to 
the X-chromosome dose [6, 8, 9]. The diplo-X dose of XSE turns SxlPe on in females 
while the haplo-X dose of XSE keeps SxlPe turned off in males. SxlPe produces a brief 
pulse of SXL before it shuts off and a subsequent activation of SxlPm takes place by the 
start of cellularization [10, 11]. The transient activation of SxlPe is the primary decision 
that helps establish the female sexual choice and reiterates this decision through 
maintenance and the rest of development by SxlPm.  
 
SxlPm comes on in both sexes but earlier in females than males, briefly before SxlPe shuts 
off [11]. This overlapping event may be important to ensure a smooth transition, making 
the timing of SxlPe activation even more significant. In males, the SxlPm transcripts are 
spliced by default to include a premature stop codon within the third exon, the male 
specific exon and results in a truncated non-functional SXL (Fig. 1.1). On the contrary, in 
females, the initial burst of SXL protein from SxlPe directs female mode of splicing, of 
the SxlPm transcripts by skipping the male specific exon [12-14]. SXL being an RNA 
binding protein, recognizes the poly(U) rich sites that are located >200 nucleotides 
downstream and >200 nucleotides upstream of the third exon [14, 15]. The binding of 
SXL to these sites and its interaction with other general splicing factors like U1 snRFP 
and SNF, cause the third exon to be excluded from the final transcripts and lead to the 
production of functional SXL [16, 17]. The functional SXL continues to auto-regulate the 
splicing of its own transcripts, which helps maintain SXL expression from SxlPm in the 
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rest of the female’s life (Fig. 1.1). Overall, the transient activation of SxlPe provides 
sufficient SXL to trigger an autoregulatory feedback loop, which enables the continuity of 
SXL generation from SxlPm [12, 13, 18]. Therefore, the establishment of autoregulation 
plays a pivotal role in converting the X-counting response of SxlPe to sexual dimorphism. 
 
Sxl target genes and dosage compensation 
SXL, as an RNA-binding protein, is capable of regulating the alternative splicing of not 
only its own transcript but also its immediate target gene, transformer (tra) [14, 19, 20]. 
A cascade of sex-specific splicing events starting from Sxl directed tra splicing is 
responsible for most of the sexual dimorphism. In females, SXL protein directly binds to 
tra pre-mRNA, directing female-specific splicing to produce active TRA protein.  In 
males, default splicing takes place in the absence of SXL, producing truncated, non-
functional TRA protein [19-21]. TRA also functions as an RNA-binding protein and the 
functional TRA in turns regulates the alternative splicing of its downstream target, 
doublesex (dsx) and fruitless (fru) [14, 22, 23]. The presence of TRA in females induced 
the production of female isoform, DSXF and FRUF, while the absence of TRA in males 
led to default splicing and production of male isoform, DSXM and FRUM (Fig. 1.2). DSX 
protein isoforms regulate the development of sexual characteristics both by activating 
genes that promote the same sex and repressing genes that are involved in the 
differentiation of the opposite sex [24, 25]. FRUF is non-functional and FRUM is known 
to be specifically expressed in the central nervous system (CNS) to control sexual 
orientation and male courtship behavior [26, 27].  
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Fig. 1.2: Somatic sex determination hierarchy 
(Top panel) In female flies, production of functional SXL is maintained by an autoregulatory 
feedback loop. In the presence of SXL, functional TRA protein is produced and it directs the 
female-specific splicing of transcripts from dsx and fru. SXL also ensures no dosage compensation 
in females by blocking msl2 translation. (Lower panel) In male flies, SXL is absent. No functional 
TRA is produced and dsx and fru are spliced to default male mode. Translation of msl2 also takes 
place, which results in dosage compensation.  
 
 
SXL also controls dosage compensation through its immediate target, male-specific-lethal 
2 (msl2) [28]. Dosage compensation is an epigenetic mechanism to equalize gene 
expression between different sexes. In flies, this process is achieved by upregulating the 
transcription of the male X chromosome. In the absence of SXL, males are able to produce 
MSL2 protein, which works in conjunction with MSL1, MSL3, MLE, MOF and 
noncoding RNAs, roX1 and roX2 to assemble a ribonucleoprotein dosage compensation 
complex (DCC) [29-33]. DCC specifically associates with male X chromosome and 
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mediates the H4 acetylation at lysine 16 (H4K16ac), which facilitate the hyper 
transcription of the single X chromosome [34-36]. However, active SXL blocks msl2 
mRNA translation in females, ensuring that no dosage compensation takes place (Fig. 1.2) 
[37].   
 
Nature and regulation of the dose-sensitive promoter, SxlPe 
Sxl is at the top of sex determination cascade, modulating all aspects of somatic sex 
differentiation and dosage compensation [5, 6, 28, 38]. The on/off state of Sxl is 
determined by counting the number of X chromosomes [9]. Although the difference 
between haplo-X dose and diplo-X dose is subtle, SxlPe is able to discern the dose 
difference and elicit an all or none response. Failure to properly sense the X chromosome 
dose at SxlPe can disrupt Sxl expression and affect the downstream regulatory events to 
establish the correct cell fate. Given the key role of SxlPe in initiating sex determination, 
tremendous efforts have been made to interpret the dose-sensitivity nature and 
transcriptional regulation of SxlPe. 
 
XSEs and other SxlPe regulators 
The decision of whether or not to activate SxlPe depends on the X-chromosome dose. 
Current research indicates that SxlPe activity is primarily determined by the collective 
dose of four X-linked signal elements (XSEs), while several other activators and 
repressors also work in concert to mediate SxlPe activity (Fig. 1.3). 
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Fig. 1.3: Positive and negative regulators of SxlPe 
XSEs, sisA, sc, runt and upd activate SxlPe along with the maternal factor, da and stat. 
Zygotically expressed dpn and maternally deposited gro function as SxlPe repressors.  
 
 
The four XSEs, sisterless A (sisA), scute (sc or sisB), runt and unpaired (upd or sisC), 
function to activate SxlPe [39-44]. The XSEs are defined by the following characteristics; 
it exerts a zygotic effect on sex determination and acts early during embryogensis; 
decreasing the dose of the gene results in female-specific lethal effect; increasing the dose 
of the gene affects male viability [5, 41]. Among the four XSEs, SisA and Scute are the 
two strongest activators that are indispensable for SxlPe activation. Runt and Upd are 
weaker activators that show limited or spatial effects on SxlPe activity. 
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sisA was discovered as a key XSE due to its sex-specific lethal characteristics. sisA 
mutants show reduced female viability while duplication of sisA has a male-specific lethal 
effect [6, 41, 45].  In situ hybridization showed sisA expression was first detected at 
nuclear cycle 8 and peaked at cycle 12. In cycle 14, the expression began to disappear in 
somatic nuclei and was eventually restricted to only yolk nuclei [42, 45]. The peak of sisA 
expression overlaps with the onset of SxlPe transcription, which further support its crucial 
role in regulating SxlPe activity. The later expression of sisA in yolk is not sex-specific 
and is associated with midgut formation [45]. SisA is a basic leucine zipper (b-Zip) protein 
transcription factor and it is predicted to regulate SxlPe by forming heterodimer with a 
protein partner [42, 46]. However, the dimerization partner of SisA is still yet to be 
discovered. 
 
Scute shares similar genetic characteristics as sisA. Loss-of-function mutation of sc is 
homozygous female lethal while sc duplication shows a strong male lethal effect in 
combination with sisA or Sxl duplication [41]. The temporal expression profiles of sc and 
sisA are also identical. Sc transcripts first appear at cycle 9, reach the peak at cycle 12 and 
decrease rapidly in early cycle 14 [9, 42]. The early expression of Sc before the first pulse 
of SxlPe activation is consistent with its role in initiation of SxlPe activity. At the 
molecular level, Sc is a better characterized XSE compared to sisA. Sc encodes a basic 
helix loop helix (bHLH) transcriptional factor, which heterodimerize with maternally 
deposited Daughterless (Da) and directly activate SxlPe via DNA binding [41, 47]. Sc/Da 
heterodimer is also known to activate other target genes during neurogenesis [48-50].   
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Runt was first identified as a pair rule gene known for its regulatory role in segmentation. 
Early runt expression is also found to be responsible for SxlPe activity as SxlPe expression 
was greatly reduced or completely eradicated in the central region of runt null mutants 
[40]. This matches the expression of runt in the central region of the embryo during cycle 
13 [51]. The restricted expression pattern of runt and its relatively late onset suggest that 
runt’s role is to maintain and reinforce uniform SxlPe expression, presumably in the 
central region. While losing one copy of scute and one copy of sisA kills majority of the 
females, the female-specific lethal interaction between runt and scute or sisA is 
comparably less, making runt a weaker activator than scute and sisA [40, 52]. RUNT is a 
DNA binding protein that belongs to the RUNX family. Although RUNT is previously 
believed to regulate SxlPe by direct binding as a heterodimer [53], our recent work 
suggests that Runt functions to activate SxlPe by antagonizing the corepressor Groucho 
(Gro) via its WRPW domain (Erickson, unpublished).  
 
Among all four XSEs, upd exhibits the weakest genetic interaction with the other XSEs 
and Sxl [44]. Instead of encoding a transcription factor like all the others, upd encodes a 
ligand of the Jak-Stat signaling pathway and modulate SxlPe expression via the activation 
of its downstream target, Stat [43, 44, 54]. The binding of Upd to receptor stimulates the 
Jak kinase, Hop, to activate the maternally supplied transcription Stat92E by 
phosophorylation [55]. SxlPe expression is compromised in Jak/Stat mutations, upd, hop 
and stat, but the effect is moderate and reduction of SxlPe only occurrs in cycle 14 in the 
central part of the embryo [43, 44, 54]. In situ hybridization reveals that upd expression 
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does not start until cycle 13, which is after the onset of SxlPe [54]. Therefore, upd is 
regarded as a reinforcement element that is involved in maintaining and fine-tuning SxlPe 
expression but is not required for the initiation of SxlPe.  
 
diminutive (dm) encodes Drosophila bHLH transcription factor Myc and is claimed to be 
a newly found XSE [56]. However, our lab failed to observe the synergistic female lethal 
interaction between dm and other XSEs that has been published. Furthermore, the 
expression profile of dm indicates that dm is not zygotically expressed during SxlPe 
activation [57]. Hence, Myc probably regulates SxlPe unlike an XSE, but via maternal 
effects.  
 
The maternally deposited zinc-finger protein Zelda is a transcription factor that functions 
as a global activator of early zygotic genome. Depletion of maternal Zelda down-regulates 
the activity of many genes involved in cellularization, sex determination and pattern 
formation, which lead to early development defects in embryos [58]. Zelda can 
specifically bind to TAGteam motif, which is abundant in the upstream region of many 
early expressed genes, including Sxl and sc [58-60].  Although Zelda is shown to regulate 
gene activation by promoting nucleosome depletion and increasing chromatin 
accessibility [61-63], the mechanism of SxlPe regulation by Zelda is still under 
investigation.   
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Negative regulators play important roles in adjusting SxlPe activation threshold in 
opposite sexes to ensure that the two dose differences can be accurately distinguished and 
SxlPe is activated in a female-specific manner. The two key negative regulators are 
maternally deposited Groucho (Gro) and zygotically expressed Deadpan (Dpn).  
 
As a repressor, elimination of maternal Gro causes ectopic SxlPe expression in males and 
earlier shift of SxlPe onset in females [64]. Gro is a Gro/TLE family corepressor that lacks 
DNA binding domain. Its recruitment to DNA is through the interaction with several other 
DNA binding proteins [65-67]. Gro is proved to be able to interact with C-terminal 
“WRPW” motif [65, 68], which is present in both Runt and Dpn. It is proposed that Dpn 
recruits Gro to SxlPe to uplift the repression threshold in males [64] while Runt contributes 
to SxlPe activation in females by antagonizing Gro-mediated repression (Erickson, 
unpublished).  
 
Dpn, which encodes a bHLH transcription factor from Hairy-Enhancer of Split (HES) 
family, is the only autosomal gene that is found to inhibit Sxl activity [10, 64, 69, 70]. dpn 
mutant males show inappropriate SxlPe expression, although the level of ectopic 
expression is relatively less compared to the males with no maternal Gro [10, 64, 69]. The 
initial transcription of Dpn is only detected around cycle 12 and it exhibits higher level of 
activity in the central region than the anterior and posterior during its peak in cycle 13 [10, 
69]. The late onset of Dpn and its comparably weak effect on SxlPe indicate that other 
inhibitors exist to modulate early repression along with Gro.  
  12 
Sxl expression from the SxlPe promoter  
In females, SxlPe expression begins at nuclear cycle 12. At this time, nascent transcripts 
are detected in some of the embryos as faint nuclear dots, by in situ hybridization. Also, 
SxlPe expression at the two X-chromosomes in the nucleus occurs independently, leading 
to a differential expression in the form of one/two nuclear dots at the early stages. By cycle 
13 all the nuclei express two nuclear dots and the intensity of their expression steadily 
increases until early cycle 14. At mid cycle 14, SxlPe transcription ceases and the nuclear 
dots disappear [9, 42, 54].  
 
    
 
Fig. 1.4: SxlPe expression in females 
Nuclear dots in the images represent nascent SxlPe transcripts. SxlPe expression starts at nuclear 
cycle 12 and ceases at mid cycle 14.  
 
 
SxlPe - structure and nature of signal sensing 
The expanse of SxlPe enhancer region maps ~5kb upstream of the transcription start site 
in the early exon, E1 of Sxl. This regulatory region acts as a shared enhancer between the 
establishment promoter, SxlPe and the maintenance promoter, SxlPm [11]. SxlPm is 
housed upstream of SxlPe, at the end of the shared enhancer region. Although, 
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transcription factors respond to cis-sequences that span the breadth of the enhancer region, 
the 3kb region upstream of the transcription start site is essentially thought to be the 
regulatory region of SxlPe.  
 
A shorter 1.4kb region when fused to lacZ drives expression comparable to the 
endogenous and has been popularly used to study SxlPe activity in the past [47, 71]. The 
cis regulatory sequences along the 1.4kb region comprises of two prominent clusters, a 
proximal 400bp region and a distal region between 0.8 and 1.0kb. Functionally, the 400bp 
region provides sex specificity but drives a low, non-uniform lacZ expression. The 
additional regulatory sequences comprised within the distal region supports and elevates 
lacZ expression to a more or less endogenous expression pattern [47, 71, 72]. The distal 
region thus functionally signifies an increase in promoter strength. 
 
The SxlPe enhancer region contains reiterated cis acting sequences that are targets of both 
positive and negative regulators. The two key XSEs, sisA and scute’s interaction at SxlPe 
was demonstrated in Estes et al., using the sex-specific, 0.4kb-lacZ construct. A decrease 
in sisA and scute gene dose caused reduction in levels of lacZ expression, validating that 
the two XSEs act through the 0.4kb region [71]. Although, genetic evidence supports sisA 
interaction at SxlPe, it remains unknown if this interaction is direct. Also, the binding sites 
of sisA along SxlPe are not detailed due to our lack of knowledge about its dimerization 
partner.  
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The cis-interactive sites of Scute are well characterized along the SxlPe promoter. Scute 
and its heterodimeric partner bind eleven sites within the 1.4kb region, upstream of the 
transcription start site [47]. Six of the binding sites are present in the 0.4kb region while 
the rest are distributed between the 0.8kb and 1.1kb region (Fig. 1.5). The binding 
sequences are a combination of canonical, E-box and non-canonical sequences, although 
they are predominantly non-canonical in nature. Functionally, both these sequences are 
pertinent to cis-regulation by Sc/Da [47].  
 
 
 
 
Fig. 1.5: The cis regulatory binding sites at SxlPe  
Schematic representation of the regulatory binding sites along 1kb SxlPe. Sc/Da sites (blue), Stat 
sites (yellow), Dpn sites (red) and Zelda sites (green) are shown. 
 
 
Activator, STAT has three sites mapped within the 1.4kb enhancer region, located at  
-253, -393 and -428bp respectively [54]. Only one of the STAT sites is present in the 
prominent 400bp region while the other two sites are the only one’s present in between 
the proximal and distal binding site clusters (Fig. 1.5). The specific distribution of the 
STAT sites could indicate a regulatory significance as to why the STAT sites are 
dispensable for initial activation of SxlPe. Yet, all we know is that mutated STAT sites are 
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known to cause moderate reduction in SxlPe activity, mostly in the central region of the 
embryo [54].  
 
XSE, RUNT has similar effects on SxlPe activity, much like STAT.  It too is not needed 
for initial activation of Sxl and it appears to affect Sxl activity in the central broad region 
of the embryo [40]. However, no consensus RUNT binding sites have been characterized 
along the SxlPe enhancer.  
 
Drosophila Myc, also known as Diminutive (Dm), is believed to be an activator of SxlPe. 
ChIP experiment showed that Myc is associated with the region that located around -96bp 
upstream of SxlPe start site. Although Myc binding sites at SxlPe are not identified, it is 
proposed that Dpn binding site 1 and 2 might be putative Myc binding sites [56]. 
 
The repressor Dpn binds SxlPe and all the four functional Dpn sites identified are located 
within the proximal 400bp enhancer region at -110, -121, -160 and -330bp (Fig. 1.5). 
Among these Dpn binding sites, sites 1 and 2 are canonical while sites 3 and 4 are non-
canonical in nature [64].  
 
TAGteam sites are bound by the transcriptional activator, Zelda and the SxlPe enhancer 
has a cluster of them present within 250bp of the transcription start site [59]. The cluster 
consists of a total of four sites, the CAGGTAG, tAGGTAG and a CAGGcAG doublet 
(Fig. 1.5). Mutations in TAGteam sites affected SxlPe activity when tested using the 
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1.4kbSxlPe-lacZ transgenes. Mutation in all of the TAGteam sites showed a compromised 
sex specific ratio as they were fewer stained embryos (females) with very low levels of 
lacZ expression. Mutated CAGGTAG and tAGGTAG proved to be less severe as it 
retained the sex specific ratio but had reduced levels of lacZ expression. The CAGGcAG 
doublet when mutated had the least effect with only a marginal reduction in lacZ levels 
[59]. The effect of the mutated doublet was harder to assess as it bordered the Sc/da, E-
box site 3.  
 
Regulatory model of SxlPe 
The success of SxlPe regulation in females largely depends on the X-chromosome 
counting. This dose-sensitive activation of SxlPe is often quoted as a textbook example of 
how small, two-fold differences in XSE protein concentration controls developmentally 
significant cell fate decisions. However, the mechanism by which such small changes in 
protein concentration regulate and cause the all-or-none response still remains a mystery 
[6, 42, 53, 73, 74].  
 
 
  17 
                      
 
 
Fig. 1.6: Regulatory model of SxlPe 
(Top Panel) The level of XSEs in females is sufficient to surpass the initial repression threshold 
set by the repressors like Gro and activate SxlPe. Activated SxlPe is likely to increase histone 
acetylation and further dampen Gro-medicated repression. (Lower Panel) The level of XSEs in 
males is not sufficient to overcome the initial repression. Maternal Gro, along with zygotically 
expressed Dpn further maintains the high repression threshold in cycle 13 and 14 to ensure that 
SxlPe remain inactive. 
 
 
Our laboratory’s theoretical model illustrates the possible mechanisms that help establish 
the sex specific regulation of SxlPe. The model is defined, based on the concept of signal 
amplification through the action of the maternal co-repressor Gro. Gro and the maternal 
supplied bHLH repressors establish the initial threshold for SxlPe activation. The 
increasing XSE concentration due to the double dose of X in females aids in surpassing 
the threshold and transcription is initiated. Once initiated, the transcriptional activation is 
maintained by the accumulation of continuously translated XSE proteins and the 
subsequent dampening of Gro mediated repression. Essentially, the dampening of 
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repression supplemented with the raising XSE’s triggers a positive feedback loop that 
ensures elevated transcription - evidently a form of signal amplification [64]. The exact 
mechanism that supports the antagonizing of Gro mediated repression remains unknown. 
We believe that the transcriptionally active SxlPe in females potentially triggers histone 
acetylation and this chromatin modification could prevent Gro binding and ultimately 
dampen the repression.  
 
In case of males, the single dose of X chromosome produces insufficient XSEs to 
overcome the initial repression. As nuclear cycles progress through cycles 13 and 14, the 
repression is further strengthened by Gro and the zygotic repressor Dpn. This ensures that 
the increase in XSEs is unable to compete with the higher repression levels and SxlPe 
remains inactivated [64].  
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CHAPTER II 
SEX LETHAL TRANSGENE SYSTEM 
 
Analyzing or quantifying the levels of SxlPe activity, as it dynamically changes during the 
nuclear cycles 12-14 is challenging. Past attempts to study the regulatory role of SxlPe 
relied largely on the use of lacZ promoter fusions. While, transgenic fusions provided 
several insights pertaining to the general spatial-temporal pattern and timing of Sxl 
expression in the developing embryo [47, 59, 64, 71], they suffered from several 
limitations. 
 
Detecting nascent transcripts with lacZ is difficult yet the ability to do so is essential to 
understanding exactly how and when SxlPe is turned on and off.  Analysis of the timing 
of SxlPe activity from the endogenous locus where nascent transcripts can be easily 
observed, has helped define the fundamental nature of the sex determination signal [9] and 
revealed important insight into the mechanism of X-signal amplification [64].  
Quantification of lacZ expression is difficult as wild type and mutant lines need to be 
analyzed separately in different animals. With traditional P-element based transgenes the 
problem was compounded by the fact that each line inserted into a unique genomic locus, 
necessitating analysis of multiple insertions to compensate for a range of chromosomal 
position effects.  Finally, promoter fusions cannot fully make use of the genetics - the 
fundamental strength of Drosophila as an experimental system. To give one illustration, 
it is impossible to rigorously define promoter sequences as both necessary and sufficient 
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using promoter-lacZ fusions as they allow no direct assessment of genetic function.  
Overcoming these concerns was our intent in creating a Sxl transgene system, that would 
allow advancements towards complete, functional validation of SxlPe. 
 
Features of the SxlTG system 
In developing an advanced system, the transgenic constructs were created with the entire 
Sxl locus including both upstream and downstream flanking regions.  The transgenes 
should thus be fully functional allowing full application of the molecular and genetic tools 
available to study the native locus: the ability to detect nascent transcripts, measure mature 
mRNA levels and assess actual biological function.  We incorporated the PhiC31 mediated 
recombination system to allow the integration of all transgenic constructs at the same 
locus, as both a means to facilitate direct comparisons between mutant and wild-type 
transgenes and to eliminate discrepancies arising from the influence of the surrounding 
chromatin on SxlPe activity.  
 
In order to establish a direct standard for quantitation and comparison of SxlPe expression, 
the system was designed to detect mutant and wild type expression, side by side in every 
nucleus of the developing embryo.  The differentiation between the two transgenes were 
made possible by exchanging the conserved region containing Exon E1 through A2 with 
corresponding sequences from related fly species.  This served the dual purpose of 
retaining normal Sxl regulation and function while allowing allele specific detection of the 
transgenes using in situ hybridization (Fig. 2.1).  
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Fig. 2.1: Sxl transgene for quantitation of allele-specific expression 
A) Control & experimental transgenes: 41.9kb construct, included the 23.5kb Sxl gene. 5 kb 
from Pm through Pe and exons E1 and exon A2 is detailed. D. melanogaster sequences from 
exon E1 through exon A2 were replaced by the same segments from D. persimilis (red) and D. 
eugracilis (green), allowing creation of allele-specific probes. B) Analysis of binding site 
mutations: Decreased (or delayed) nascent transcripts and lowered mRNA levels measured by 
allele-specific probes (green, red) using fluorescent in situ hybridization. 
 
 
Design and development of the Sxl transgene system 
The transgene system is equipped with two Sxl transgenes, one of which serves as the wild 
type (control transgene) and the other carries the engineered Sxl mutations (experimental 
transgene) to be analyzed. The transgenic constructs are created using galK 
recombineering in a P(acman) II vector [75, 76]. The Pacman vector was chosen because 
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it facilitated PhiC31-mediated integration of large genomic fragments [77] and its low 
copy number in E. coli allowed genetic manipulation via galK recombineering [75, 76].  
My plan was that the transgenes carry the entire Sxl locus, ~ 20kb sufficient upstream and 
downstream flanking region so that Sxl would be both functional and insulated from any 
chromosomal effects due to the site of insertion. When I began, it was not known how 
much DNA upstream or downstream of Sxl would be needed to preserve full function. 
Accordingly, I adopted a trial and error method.  I started out with a 92kb SxlTG construct, 
which included about 68.5kb of flanking region. The 92kb construct failed to yield 
transformants, owing to its large size and/or limitations of the commercial injection 
services we used. I decreased the construct size further to 79kb and 50kb, by deleting the 
flanking regions from both sides of the Sxl locus but these lines did not yield any 
transformants. Finally, a 41.9 kb Sxl construct yielded a viable transformant and this 
construct has since proven reliable for obtaining transformants from commercial injection 
services.  All the transgenes detailed in my thesis have been integrated into the attP40 site 
on chromosome 2 and is our desired site to maintain a comparison standard (Fig. 2.2).  
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Fig. 2.2: Integration of Sxl transgene into the Drosophila genome 
A) Sxl transgene construct, 41.9kb is detailed. It included the 23.5kb Sxl gene, flanked by 4.5kb 
upstream and 13.9kb downstream sequences. B) The attB-P[acman] is integrated at the attP 
docking site in flies expressing PhiC31 integrase. The SxlTG construct and the white+ marker are 
introduced into the target location in the fly genome and the white+ flies are selected. 
 
 
galK recombineering 
galK recombineering provides a rapid method for creating small or large deletions, 
insertions as well as simple sequence changes to be introduced onto the transformation 
vector containing Sxl. It embodied a two-step process (Fig. 2.3). In the first step, the E.coli 
galK gene was inserted into the Sxl-P(acman) construct at the region where a desired 
mutation or a particular change is to be targeted. Recombinant bacteria were selected for 
the presence of galK by plating on minimal media containing galactose as the only carbon 
source. In the second step, galK was replaced by a repair fragment which was generated 
A. Sxl transgene construct
B. PhiC31 mediated transgenisis
PhiC31 mediated 
transgensis
41.9kb
Sxl
23.5kb
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by PCR and carried the corresponding engineered change. The recombinant bacteria here 
were selected by plating on minimal media containing 2-deoxy-galactose which is toxic 
to galK+ cells. The colonies were further confirmed by PCR and sequencing [76].  
 
 
 
Fig. 2.3: Introducing changes in the Sxl sequence by galK recombineering 
A) galK+ fragment with 50bp homology to the flanking regions of the target site was introduced 
in the Sxl gene by homologous recombination. Selected for galK+. B) galK replaced with the 
fragment containing the desired sequence changes via homologous replaced recombination. 
Selected for galK- (2-deoxy-galactose resistance).  
 
 
Functionality of the Sxl transgene system 
The transformants were tested for full function by performing genetic complementation 
tests in Sxl mutant backgrounds, Sxlf7bO and Sxlf1. Sxlf7bO is a deletion mutation with the 
deletion of the entire Sxl transcription unit and an undefined amount of flanking DNA [78] 
while Sxlf1 is a null mutation that blocks the inclusion of exon 8 mRNA splicing of all Sxl 
transcripts. Both, Sxlf7bO and Sxlf1are female lethal. The transgene fully complemented the 
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two null Sxl mutations, as one copy of the SxlTG was able to fully rescue female lethality 
(Table 2.1) with the resulting fly lines appearing fully fertile.   
 
 
Table 2.1: Sxlf1 and Sxl7bO female viability data 
 
   
Progeny from the cross Sxl -/+; +/+ ×  Sxl -/Y; TG/+ were counted. The Sxl - alleles 
tested were y w cm Sxlf1 ct/Binsincy and y w cm Sxl7bO/Binsincy.  
 
 
Designing allele specific markers and its associated challenges 
The first exon and intron of SxlPe transcripts, and the second exon of Pm-RNA of the 
transgenes are known to be conserved [79] and this region was swapped in each of the 
transgenes for corresponding sequences from another fly species. A variety of species, 
phylogenetically far and near were used because the outcome of the change on Sxl function 
could not be predicted. The transgenic lines with changes from D. ananassae, D. 
persimilis and D. virilis, failed to complement Sxlf7bO and Sxlf1 but those from D. eugracilis 
and D. erecta complemented Sxlf7bO and Sxlf1. 
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In theory, interchanging exons should not have affected Sxl function but some of them 
did. Further genetic tests were carried out to learn, if these transgenic lines complemented 
Sxlf9.  Sxlf9 is a loss of function allele that is defective for the early function of Sxl and 
thereby affects the establishment of female identity [20, 80].  It carries a nonsense 
mutation in exon E1 that truncates the early form of Sxl protein after amino acid 21.  As 
expected, the transgenic lines with changes from D. eugracilis and D. erecta 
complemented Sxlf9 but so did D. persimilis (Table 2.2). This showed that the changes 
from D. persimillis did not affect the early function of Sxl, and so can be used to study 
SxlPe activity. Transgenic lines with changes from D. ananassae, and D. virilis, however, 
failed to complement Sxlf9 and could not be used.  
 
 
Table 2.2: Analysis of the transgenic lines with the designed allele-specific changes 
in E1 to A2 region 
 
Species source for the 
allele-specific changes 
Complemented 
Sxlf9 
Complemented 
Sxlf7bO & Sxlf1 
Specific detection by 
in situ hybridization 
D. melanogaster + + + 
D. persimilis + - + 
D. ananassae - - n/d 
D. virilis - - n/d 
D. eugracilis + + + 
D. erecta + + + 
D. willistoni - - n/d 
 
          + denotes a positive outcome, - denotes a negative outcome and n/d denotes not done. 
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SxlPe activity of the Sxl transgene system followed by in situ hybridization  
The genetic tests characterized the viability function of the transgenes in detail. To analyze 
the SxlTG further at the molecular level, SxlPe expression from the transgenes was 
observed by in situ hybridizations. In situ hybridization experiments were performed on 
the transgenic line with changes from D. persimilis (Sxl-Persi-TG), D. erecta and D. 
eugracilis (Sxl-Eug-TG) in a wild type background. The SxlPe activity of the Sxl-Persi-
TG and the Sxl-Eug-TG lines mimicked the endogenous Sxl expression observed in wild 
type embryos (Fig. 2.4). In case of the transgenic line with changes from D. erecta, the 
probe used in the experiment, detected transcripts both from the SxlTG as well as the 
endogenous loci. The high sequence similarity between D. melanogaster and D. erecta 
was indeed a limitation and attempts to design a probe to overcome this problem was 
futile. From the collective information regarding the transgenic lines, the Sxl-Persi-TG 
and Sxl-Eug-TG lines were determined as the most suited to build the SxlTG system. Sxl-
Persi-TG was the designated control and Sxl-Eug-TG, the experimental transgene. The 
experimental transgene being fully functional could be used to perform both, molecular 
and genetic analyses. 
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Fig. 2.4: In situ hybridization showed that the Sxl transgenic lines mimicked 
wildtype SxlPe expression  
Nuclear dots represent nascent SxlPe transcripts. Top row: wildtype (wt) female embryos stained 
using SxlPe probe. Middle row: Female embryos carrying Sxl-Persi-TG (control transgene) stained 
using D. persimilis SxlPe intron-exon probe. Bottom row: Female embryos carrying Sxl-Eug-TG 
(experimental transgene) stained using D. eugracilis SxlPe intron-exon probe. Nuclear cycles (12, 
13 and 14) are indicated; nuclear cycle 14 can be divided into early (£ 5min) and late (£ 30min) 
stages of cellularization cycles. 
 
 
SxlPe activity of the Sxl transgene system followed by fluorescent in situ 
hybridization (FISH)       
FISH was performed on Sxl7bO/ Sxl7bO embryos heterozygous for Sxl-Persi-TG (control) 
and Sxl-Eug-TG (experimental). The designed FISH probes, fluorescein-labeled D. 
persimilis SxlPe intron probe and dig-labeled D. eugracilis SxlPe intron probe specifically 
detected the control transgene and experimental transgenes respectively without 
  29 
hybridizing to the endogenous SxlPe and therefore could be used in any genetic 
background including wild type. Each FISH probe was attached to a different fluorescent 
dye, which allowed us to visualize the SxlPe mRNA from control (false colored as red) 
and experimental (false colored as green) transgenes in separate laser channels (Fig. 2.5). 
As a result, the SxlPe activity of both the transgenes were followed independently in every 
nucleus of the embryo using high quality FISH signals. 
 
 
              
Fig. 2.5: FISH image depicting the SxlPe activity of the Sxl transgene system 
Magnified confocal images of cycle 12, cycle 13 and early cycle 14 embryos carrying both Sxl-
Persi-TG (control) and Sxl-Eug-TG (experimental). A) DAPI staining of nucleus. B) Nuclear dots 
(green) represent SxlPe transcripts from Sxl-Eug-TG. C) Nuclear dots (red) represent SxlPe 
transcripts from Sxl-Persi-TG. D) Merged images of A, B and C. 
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Automated quantification analysis of FISH images 
The high-resolution confocal images of Sxl transgene system not only allowed qualitative 
analysis of SxlPe expression pattern but also provided the possibility of obtaining 
quantitative expression profiles for comparing our control and experimental transgenes.  
At present this aspect of my transgenic system remains incompletely developed.  Our plan 
is to continue to work with Dr. Stan Vitha of the Texas A&M MIC center to better exploit 
the potential of the system.  So far, quantification assessment of FISH images was 
achieved via ImageJ marco script developed by Dr. Vitha. To begin with, 2D image for 
each whole-mount embryo are generated by combining the maximum pixel intensity from 
every Z-stack. In the blue channel, boundaries of each nuclei were determined by DAPI 
signal to generate a nuclei mask image. Using this image, pixels from red (control) and 
green (experimental) channels could then be assigned to their corresponding nuclei (Fig. 
2.6A). Each nucleus was selected as a region of interest (ROI) and the built-in ImageJ 
function “Anaylze Particles” was performed in green and red channels separately for each 
ROI. As a result, the count of particles (nuclear dots), their area and integrated density in 
each ROI (nucleus) are determined (Fig. 2.6B) and used to calculate the percentage of the 
total expressing nuclei.  
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Fig. 2.6: Example of an automated quantification analysis  
A) Pixels from the red channel (control) were assigned to the corresponding nucleus. Each nucleus 
was selected as an ROI with boundaries determined. B) Results of “Analyze Particles” for 
Fig2.6A. 
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CHAPTER III 
THE SxlPe PROMOTER  -  ENHANCER CONNECTION IN SEX 
DETERMINATION 
 
The establishment promoter, SxlPe dictates the sexual fate decision, by sensing XSE dose 
[5, 8, 17]. The cis regulatory elements along the SxlPe enhancers are essential for XSE 
dose sensing and controlling the precise timing of SxlPe. However, our understanding of 
the roles of the specific cis regulatory elements and their contributions to regulation and 
the biochemical interactions of the XSEs is still rather primitive. 
 
Previous attempts to learn about the SxlPe promoter have been insightful [71]. Estes et al.  
used an in vivo, promoter deletion analysis to functionally dissect the regions of SxlPe 
needed for sex-specific activation. They tested a series of SxlPe promoter fragments 
carrying DNA segments ranging from 0.2kb to 3.0kb upstream of the transcription start, 
by fusing them to lacZ and assaying for β-galactosidase expression in the corresponding 
transgenic animals.  
 
The key findings of Estes et al. were, first, that a 1.4 kb SxlPe-lacZ construct behaved 
similarly to all larger SxlPe-lacZ fusions tested.  The 1.4 kb SxlPe-lacZ line was sex 
specific and strongly and uniformly expressed.  It produced levels of β-galactosidase that 
appeared to be slightly lower than the larger 3.0 ad 3.7 kb SxlPe-lacZ fusions but the 
differences, if real, were small. Deletions shorter than 1.4 kb showed declines in the levels 
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of lacZ expression and where characterized by, non-uniform expression levels along the 
anterior-posterior axis of the developing embryo. Surprisingly, the decrease in expression 
levels had little or no effect on sex specificity until promoter function was lost. Even a 
minimal SxlPe construct, 0.4 kb, maintains sex specificity, in spite of driving a low, non-
uniform level of lacZ expression [71].  
 
The second key finding of Estes et al. was that the minimal promoter segment required for 
sex-specific expression contained 0.4 kb upstream of the SxlPe start site. While the 0.4kb 
SxlPe-lacZ fusions maintained sex-specificity, their levels and patterns of expression were 
dramatically different from the 1.4, 3.0 and 3.7 kb fusions. The 0.4 kb expressed weakly 
and non-uniformly, with expression in some lines detectable only in the anterior regions 
of the embryos. An unexpected finding was that the 0.4kb lines showed higher levels of 
expression than the 0.8kb SxlPe fusions. This was attributed to the region from 0.4-0.8kb 
carrying negative regulatory sites proteins whose presence inhibited the function of 
positively acting XSE sites site in the 0.4kb promoter region.  This, combined with a 
subsequent analysis of Sc/Da binding sites [47] led to the idea that SxlPe has a basal 0.4kb 
promoter unit, that functions as the primary determinant of female sex specificity and an 
augmentation region located between 0.8 and 1.4kb upstream, that drives the strong 
expression uniform expression needed for full SxlPe function [47, 71].  
 
While these studies, provided valuable information about SxlPe structure, the use of lacZ 
fusions imposed limitations of what could be learned. Analysis of β-galactosidase activity 
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required that embryos be assayed well after the period when SxlPe is active.  Subsequent 
analyses using in situ hybridization to lacZ mRNA [43, 54, 64] confirmed these general 
findings, however, because nascent transcripts cannot be easily detected with the 
intronless LacZ gene, key issues related to the precise timing of SxlPe expresion by the 
promoter constructs could not be assessed. Perhaps most important, the use of promoter 
fusions removed SxlPe from its normal chromosomal context and precluded any genetic 
assessment of whether the sequences were necessary or sufficient for SxlPe activity. 
 
Defining the regulatory framework of the promoter and validating the promoter- enhancer 
interactions that contribute to regulation is of paramount importance to understanding 
SxlPe regulation. My approach was to use the Sxl transgenic system to reanalyze the 
previously tested promoter segments, to validate their corresponding findings.  
 
Creating SxlPe promoter deletions in the SxlTG  
A series of promoter deletions, spanning from a small 0.2 kb fragment to a large 3.7 kb 
segment, were tested using the Sxl transgene system. The SxlPe deletion transgene (delPe-
SxlTG) constructs were engineered by deleting DNA upstream of the desired segment, 
including the distal SxlPm promoter. As a result, the gene upstream of SxlPm, CG4615 
was fused directly with the desired SxlPe segment. This allowed the analysis of the desired 
promoter elements in a closer to normal genetic context and allowed them to be analyzed 
without interference from the upstream SxlPm [11]. 
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All the promoter deletion constructs were created in the SxlTG and also in the experimental 
TG, Sxl-Eug-TG by galK recombineering. The idea was to use the SxlTG lines in the initial 
complementation analyses to eliminate any concerns that the related sequences from D. 
eugracilis in the region from exons E1 through L2 might influence promoter activity. Once 
the D. eugracilis and D. melanogaster deletion lines were confirmed to be genetically 
equivalent, either the Sxl-Eug-TG or SxlTG were used for in situ analysis according to 
experimental utility.  
 
Initially, five promoter deletion constructs were created with 0.8 kb, 1.1 kb, 1.4 kb, 3.0 kb 
and 3.7 kb of DNA upstream of SxlPe (designated as SxlPe0.8kb-SxlTG and so on) (Fig. 
3.1). Our expectation, based on the findings of Estes et al. [71] and Yang et al. [47], was 
that this series would span the range from a fully functional to severely defective and allow 
us to define the minimal segment actually needed to provide SxlPe function. The number 
of base pairs of SxlPe included in the deletion constructs are the same as the ones described 
in Estes et al. Typically, for a SxlPe0.8kb-SxlTG construct, 800 bp upstream from the first 
exon of the embryonic transcript was included and the termination site of the construct 
was also decided by the restriction site they used for every fragment respectively.   
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Fig. 3.1: Schematic representation of SxlPe0.8kb, SxlPe1.1kb, SxlPe1.4kb, SxlPe3.0kb and 
SxlPe3.7kb promoter constructs in the SxlTG 
The red segment represents the SxlPe enhancer region included in the constructs. Sequences 
upstream from the first exon of SxlPe was included and the termination site of the construct was 
decided by the restriction site used for the corresponding fragments in Estes et al. The blue segment 
represents the region upstream of SxlPm. 
 
 
Genetic tests of the effects of SxlPe deletions on promoter activity 
Whether or not a SxlPe deletion transgene construct is truly sufficient to drive Sxl 
expression can be answered by its ability to complement Sxl mutations defective for the 
early (establishment) isoform of SXL. Therefore, the delPe-SxlTG constructs were 
subjected to a range of complementation tests to analyze their effects on female viability. 
Since, the delPe-SxlTG lack a functional SxlPm promoter, these constructs cannot 
complement Sxl null mutations such as, Sxlf1 or the deletion mutation, Df(1)Sxl7B0. 
(Control experiments confirmed that deletion of SxlPm leaves the deletion constructs 
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unable to provide the Sxl maintenance function needed to complement Sxlf1 and Sxl7BO 
(data shown in Appendix A)). 
 
Instead I used Sxlf9, an early defective allele carrying a nonsense mutation that truncates 
the Sxl exon E1 coding sequence at amino acid 21. Sxlf9 thus fails to provide the SxlPe-
derived protein needed to initiate autoregulatory splicing but is capable of providing all 
other forms of Sxl protein.  Complementation tests were carried with the Sxlf9 mutants with 
the results shown in Table 3.1. In each case a single copy of the respective delPe-SxlTG 
completely rescued female lethality as did the control SxlTG with all Sxl sequences intact. 
This proved that the delPe-SxlTGs were each capable of providing sufficient Sxl function 
to rescue the early-defective Sxlf9 allele, a result not anticipated based on the phenotypes 
observed for SxlPe-lacZ fusions [47, 71]. 
 
 
Table 3.1: All delPe-SxlTG rescued female lethality in Sxlf9 mutant females 
 
 
Crosses  w Sxlf9 ct/Binsincy; +/+ ×  w Sxlf9 ct /Y; TG/+ 
Numerical data represent percentage of female viability. Numerical data in parenthesis represent 
the number of viable females.  
The siblings without transgenes were used as reference. 
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My finding that the 0.8 kb SxlPe TG rescued Sxlf9 was particularly surprising because the 
0.8 kb construct used by Estes et al., expressed lacZ somewhat non-uniformly and at levels 
far below those produced by the larger promoter fragments. One possible explanation is 
that the Sxlf9 mutation may not be a complete null for early Sxl function [81] presumably 
due to read-through of the nonsense mutation, and thus can be rescued by lower than 
expected levels of SxlPe expression.  A second possibility is that the 0.8 kb SxlPe-lacZ 
fusions may not have accurately reported promoter function given their artificial sequence 
context and chromosomal sites of insertion. Alternatively, it may be the case that only 
low-levels of SxlPe activity are all that is required to initiate the autoregulatory splicing 
loop in the embryo. To further test these ideas, I performed more stringent 
complementation tests and analyzed the expression from the delPe transgenes by in situ 
hybridization. As a first step, I tested the delPe constructs in the Sxl-Eug-TGs, for their 
ability to complement Sxlf9 and obtained results indistinguishable from those with the 
SxlTGs bearing only D. melanogaster DNA (Sxlf9 data for delPe-Sxl-Eug-TGs is shown in 
Appendix A). Accordingly, I used either SxlTG or Sxl-Eug-TG in subsequent experiments 
according to which was most appropriate experimentally. 
 
A more stringent test: complementing Sxlf9/Sxlf1 heterozygotes 
In the genetic complementation tests with the Sxlf9 mutant, all the SxlPe deletion variants 
fully rescued female viability.  As a more stringent test of SxlPe function I analyzed the 
ability of the SxlPe deletion TGs to complement Sxlf9/Sxlf1 heterozygotes. Sxlf1 is a null 
mutation that blocks proper splicing of all Sxl mRNAs.  Sxlf9/Sxlf1 heterozygotes should 
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be less easily rescued by low level SxlPe expression than Sxlf9/Sxlf9 females because there 
should be less residual early Sxl expression to initiate autoregulatory splicing and less late 
SXL protein to lock in and maintain stable RNA splicing [12, 18]. 
 
 
Table 3.2: Promoter deletion restores female viability in Sxlf9/Sxlf1 mutant females 
  
 
Crosses  y w cm Sxlf1 ct /Binsincy; +/+ ×  w Sxlf9 ct /Y; TG/+ 
Numerical data represent percentage of female viability. Numerical data in parenthesis represent 
the number of viable females.  
The siblings without transgenes were used as reference. 
*Similar viability results were obtained when delPe-Sxl-TGs were tested (data shown in Appendix 
A). 
 
 
I found that the five delPe-SxlTG lines all complemented Sxlf9/Sxlf1 heterozygotes, 
however, the data revealed that the smaller SxlPe0.8kb-SxlTG and SxlPe1.1kb-SxlTG 
transgenes were less effective at rescue than were the SxlPe1.4kb-SxlTG, SxlPe3.0kb-SxlTG 
and SxlPe3.7kb-SxlTG lines (Table 3.2). SxlPe1.1kb-SxlTG showed some decrease in female 
viability and it could not rescue females as well as the larger delPe-SxlTG.  
SxlPe0.8kb-SxlTG on the other hand, showed a significant decrease in percentage female 
viability (38%), much lesser than what was observed with the homozygous Sxlf9 
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complementation data (92%). This revealed that, although, the SxlPe0.8kb is sufficient for 
activation of SxlPe, it may not be a strong enhancer as the rest of the delPe-SxlTG.  
 
In situ hybridization of SxlPe deletion constructs 
The nature of SxlPe activation and SxlPe expression levels in embryos carrying two copies 
of the delPe-SxlTGs were analyzed by in situ hybridization using the D. eugracilis SxlPe 
intron probe. All the SxlPe deletion constructs initiated SxlPe expression at nuclear cycle 
12, consistent with the onset of SxlPe activity in wild type. In the progression to cycle 13 
and cycle 14, a myriad of expression levels was observed, ranging from a weak expression 
to a wild type SxlPe expression depending on the type of SxlPe deletion construct (Fig. 
3.2 and 3.3). Each of the construct-specific SxlPe expression pattern is described below.  
 
In embryos carrying the SxlPe0.8kb-SxlTG, SxlPe expression was low, non-uniform and 
missing in a large fraction of nuclei in cycles 13 and 14. Among the expressing nuclei, a 
significant number of them only activated a single copy of SxlPe, represented as a single 
faint nuclear dot. The activity SxlPe expression differed greatly between the sibling 
embryos in cycles 13 and 14 (Fig. 3.2B). Approximately 50% of cycle 13 female embryos 
activated SxlPe in a very small fraction of nuclei while the rest of the embryos expressed 
SxlPe in about half of the nuclei. Similarly, cycle 14 were characterized by 70% of the 
female embryos with half or less, nuclei expressing with the rest expressing Sxl in a larger 
fraction of nuclei. Expression was predominantly evident as one nuclear dot. The 30% 
embryos with higher SxlPe activity are probably representative of those in the Sxlf9/Sxlf1 
  41 
genetic background that produce enough SXL to successfully activate splicing of SxlPm 
transcripts and develop into adult females (Table 3.2).  
 
 
 
 
Fig. 3.2: In situ hybridization of SxlPe0.8kb and SxlPe1.1kb transgenic lines 
Nuclear dots represent nascent SxlPe transcripts. Surface views of embryos were shown in both 
20X and 100X. 100X pictures were taken at the center of the embryos unless indicated. A) Sxl-
Eug-TG female embryos exhibited a uniform wild type expression, with two nuclear dots present 
in every nucleus. B) SxlPe0.8kb females failed to activate SxlPe in a large fraction of nuclei. None 
or one faint nuclear dot was detected in these nuclei. Squares indicated the regions where 100X 
pictures were taken. C) SxlPe1.1kb failed to activate SxlPe in some of the nuclei. Squares indicated 
the regions where 100X pictures were taken. D) A schematic representation of the lateral view of 
a whole-mount Drosophila embryo. The embryo is divided into regions 1-4 according to the spatial 
expression pattern observed in SxlPe0.8kb-Sxl-Eug-TG and SxlPe1.1kb-Sxl-Eug-TG embryos. 
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A striking feature of the SxlPe0.8kb construct, was that the majority of the embryos 
exhibited a strongly anterior-biased spatial expression pattern. Most of the expressing 
nuclei were concentrated in the anterior major (region 2) and the posterior end (region 4) 
compared to the anterior tip (region 1) and the posterior major (region 3) (Fig. 3.2B). The 
observed expression pattern here are consistent with the notion that SxlPe0.8kb enhancer 
may not include all the required cis-regulatory elements to achieve an embryo wide 
expression pattern [47, 71]. Overall, SxlPe0.8kb is able to activate SxlPe to a sufficient level 
to rescue females strongly deficient for early Sxl function, but the enhancer is challenged 
to do so.  
 
SxlPe1.1kb is evidently a stronger enhancer than the SxlPe0.8kb as embryos carrying it show 
a substantial increase in the number of nuclei expressing, in the fraction of nuclei 
expressing two nuclear dots, and in nuclear dot staining intensity (Fig. 3.2C). Half of the 
female embryos carrying the SxlPe1.1kb-SxlTG, in both cycle 13 and 14, displayed a 
uniform, almost wild type expression with a slightly lower staining intensity of the nuclear 
dots compared to wild type. However, the other half, failed to activate SxlPe in some 
nuclei and those that expressed showed an anterior-biased spatial expression pattern, 
reminiscent of the one observed in the SxlPe0.8kb-SxlTG line. The expressing regions of the 
SxlPe1.1kb-SxlTG was expanded compared to the 0.8 kb construct, where the active nuclei 
extended all the way to the anterior tip (region 1) and also further into posterior half 
(region 3) (Fig 3.2C). This indicates that the additional 300bp does enhance SxlPe 
expression, which is perhaps not surprising in that it carries two high-affinity E-box 
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binding sites for Sc/Da (see Chapter IV), but it is still apparently not enough to completely 
restore the wild type expression in all the female embryos. The non-uniform expression in 
some of the female embryos, may be the cause of the reduced female viability obtained in 
the Sxlf9/Sxlf1 complementation test (Table 3.2).   
 
Most female embryos carrying SxlPe1.4kb-SxlTG, follow an expression pattern that is 
largely indistinguishable from wild type in both cycle 13 and 14 (Fig. 3.3B). Occasionally, 
there are embryos that have a small fraction of nuclei that are unable to activate SxlPe. 
Thus, it appears that while SxlPe1.4kb may not achieve fully wild-type expression, this has 
no impact on female viability.  Comparison of the 1.1 kb and 1.4 kb constructs suggests 
that there are regulatory sequences located between -1.1 and -1.4 kb that are needed for 
uniform strong expression of SxlPe, and in this respect our findings are similar to those of 
Estes et al [71].  Curiously, however, the identified binding sites for the strong XSE 
activator Sc/Da map within 1.0 kb of the transcription start site and are thus included in 
both the 1.1 kb and 1.4 kb constructs [47].  It could be the case that binding sites for the 
XSE protein SisA, or for maternal activators map in the -1.4 to -1.1 kb interval. 
Alternatively, it could be the case that the lower activity of the 1.1kb fragment is a 
consequence of the upstream DNA fused to it. As discussed below, I have evidence that 
the upstream sequences can act to inhibit, or partially silence, the activity of the minimal 
0.4 kb SxlPe promoter. If that is the case for the larger constructs, it may be the case that 
the sequences important for near full expression of SxlPe are actually located within the 
1.1 kb segment but that they are not fully expressed in the context of the deletions. Arguing 
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against this interpretation is that the 1.1 kb and 1.4 kb SxlPe-lacZ fusions of Estes et al. 
[71], which had completely different DNA sequences fused upstream, showed similar 
comparative strengths to what I observed. 
 
 
 
Fig. 3.3: In situ hybridization of SxlPe1.4kb, SxlPe3.0kb and SxlPe3.7kb transgenic lines 
Nuclear dots represent nascent SxlPe transcripts. Surface views of embryos were shown 
in both 20X and 100X. A) Sxl-Eug-TG female embryos exhibit a wild type expression.   
B) SxlPe1.4kb activated both SxlPe transcripts in most nuclei. C-D) SxlPe expression in 
SxlPe3.0kb and SxlPe3.7kb female embryos was indistinguishable from Sxl-Eug-TG. 
 
 
The longer length SxlPe3.0kb and SxlPe3.7kb constructs function as strong, robust enhancers 
of SxlPe, as they drove a SxlPe expression that was indistinguishable from that of the 
SxlTG that contains all the sequences needed for SxlPe expression (Fig. 3.3C and 3.3D).  
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SxlPe activity is absent in minimal enhancers, SxlPe0.2kb and SxlPe0.4kb 
The surprising finding that SxlPe0.8kb-SxlTG rescued the viability of Sxlf9 mutants, lead us 
to ask, if smaller promoter constructs could also activate SxlPe. In search for the smallest 
SxlPe deletion construct that retained sex specificity, two promoter deletion constructs, 
SxlPe0.2kb and SxlPe0.4kb were created in the SxlTG.  The promoter activity of each was 
assayed by analyzing its ability to recue homozygous Sxlf9 females. Neither SxlPe0.2kb nor 
SxlPe0.4kb complement the Sxlf9 mutants when present in one or two copies (Table 3.3).   
 
 
Table 3.3: SxlPe0.2kb and SxlPe0.4kb are not sex specific 
 
  
Crosses  w Sxlf9 ct/Binsincy; TG/+ ×  w Sxlf9 ct /Y; TG/+. 
Numerical data represent percentage of female viability. Numerical data in parenthesis represent 
the number of viable females.  
Numbers indicate the percentage of female viability. 
  
 
Adding spacer DNA to separate the SxlPe0.4kb enhancer from upstream sequences 
reinstates SxlPe activity 
Because the SxlPe0.4kb and the SxlPe0.8kb enhancer had opposite outcomes in functional 
tests, we scrutinized the sequences that differ between them. The SxlPe0.4kb contains all 
the known Sc/Da and Dpn binding in the region [47, 64] except two STAT binding sites, 
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STAT site 2 and site 3 that had minimal effect on SxlPe-lacZ activity [54].  In addition, 
the proximal 0.4 kb region is highly conserved between Drosophila species whereas the 
0.8 kb segment is not [82] (Erickson unpublished).  Additionally, Estes et al. [71] found 
that the 0.4 kb construct drove a stronger lacZ expression than the 0.8 kb version, 
suggesting that if anything, that the -0.8 to -0.4 kb segment might have negative regulatory 
sequences located within. We considered the possibility that the design of our promoter 
deletions could have juxtaposed upstream DNA that locally inhibited the expression of 
SxlPe.    
 
I tested this idea by creating the SxlPe0.4kbgalK construct. SxlPe0.4kbgalK has 1.2 kb of bacterial 
galK sequences inserted between the - 0.4 kb breakpoint and the upstream DNA in the 
context of the Sxl-Eug-TG (Fig. 3.4A). Bacterial sequences were chosen for experimental 
convenience with the expectation that the galK segment would have no influence on the 
SxlPe promoter. I found that the SxlPe0.4kbgalK-SxlTG fully rescued Sxlf9 and partially 
rescued the Sxlf9/Sxlf1 heterozygotes, suggesting that the 0.4 kb proximal construct can 
activate SxlPe to levels comparable to those of the SxlPe0.8kb-SxlTG (Fig. 3.4B and 3.4C).  
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Fig. 3.4: SxlPe0.4kbgalk promoter construct reinstates SxlPe activity 
A) Schematic representation of SxlPe0.4kbgalk promoter construct in the SxlTG. B) Sxlf9 
complementation: crosses  w Sxlf9 ct/Binsincy; +/+ ×  w Sxlf9 ct /Y; TG/+. Numbers 
indicate the percentage of female viability. The siblings without transgenes were used as 
reference. C) Sxlf9/ Sxlf1 complementation: crosses  y w Sxlf1 ct/Binsincy; +/+ ×  w Sxlf9 ct 
/Y; TG/+. Numbers indicate the percentage of female viability. The siblings without transgenes 
were used as reference. D) In situ hybridization of SxlPe0.4kbgalK transgenic lines. Nuclear dots 
represent nascent SxlPe transcripts. Surface views of syncytial nuclei were shown in both 20X 
and 100X. 
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In situ hybridization data from the SxlPe0.4kbgalK-SxlTG, proved interesting. SxlPe0.4kbgalK-
SxlTG activated SxlPe as expected given the genetic tests and the SxlPe expression 
progressed from cycle 12-14. There were clear non-uniformities in expression during 
nuclear cycles 13 and 14 but the most distinguishing feature was that the SxlPe0.4kbgalK-
SxlTG derivative had stronger and more complete SxlPe expression, than did SxlPe0.8kb-
SxlTG (Fig. 3.4D). While, the expression pattern of the SxlPe0.4kbgalK line had several 
attributes in common with the SxlPe0.8kb line a minimal enhancer, such as a large number 
of the non-expressing nuclei and the presence of numerous nuclei with only single dots, 
the SxlPe0.4kbgalK-SxlTG activated SxlPe in many more number of nuclei (~50% or higher) 
and appeared to drive stronger SxlPe expression than observed in most SxlPe0.8kb-SxlTG 
embryos. As, the nuclear dot staining intensity of this line was slightly lower than 
SxlPe1.1kb-SxlTG and the fact that none of the female embryos were able to reach a wild 
type expression, it was deemed a less effective enhancer than the SxlPe1.1kb. The 
SxlPe0.4kbgalK construct still exhibited the anterior-biased, spatial expression pattern that is 
characteristic of the SxlPe0.8kb-SxlTG construct.  
 
The results obtained clearly demonstrate the minimal SxlPe promoter sufficient to 
complement the early defective Sxlf9 allele are contained within the SxlPe0.4kbgalK-SxlTG. 
This finding also strongly suggests that DNA from CG4615, the gene upstream of and 
adjacent to Sxl had the effect of partially silencing SxlPe in at least some of our constructs. 
In particular, silencing may have influenced our comparisons between the 1.4 and 1.1 kb 
constructs (discussed above), and between the 0.8 kb, and 0.4 kb galK constructs. My 
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observation that SxlPe0.4kbgalK-SxlTG expressed more strongly than did the SxlPe0.8kb-
SxlTG is consistent with the results of Estes et al. [71] who observed, using SxlPe-lacZ 
fusions with entirely different sequences abutting SxlPe, that their 0.4 kb lines expressed 
more strongly than the longer 0.8 kb versions.  Estes et al [71] interpreted this as evidence 
that the -0.8 to -0.4 segment contained unidentified negative regulatory elements. That 
interpretation is also consistent with our findings; however, we cannot exclude the 
possibility that the -0.8 to -0.4 kb segment was simply less effective at suppressing the 
silencing DNA than was the longer galK segment. Regardless of the answer, the positive 
results obtained with the SxlPe0.4kbgalK-SxlTG define the minimal upstream DNA needed 
to complement the early defective Sxlf9 allele. 
 
SxlPe0.8kb and SxlPe0.4kgalK enhancers are sensitive to reductions in the XSE dose 
The minimal SxlPe0.8kb and SxlPe0.4kbgalK SxlPe transgenes are able to fully rescue the early 
Sxl function missing in Sxlf9 mutants despite being expressed in fewer nuclei and at 
apparently lower levels than wild type. This weak expression suggested that the function 
of the shorter SxlPe transgenes might be extremely sensitive to alterations in XSE gene 
dose.  Genetic complementation crosses were performed to scrutinize the viability of Sxlf9 
females carrying a reduced XSE dose. I examined the alleles, scM6 or runt3. The larger 
SxlPe1.1kb-SxlTG, SxlPe1.4kb-SxlTG, SxlPe3.0kb-SxlTG and the SxlPe3.7kb-SxlTG, were 
unaffected by the loss of one dose of an XSE. Full female viability was seen in every case 
(Table 3.3).  
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Table 3.4: SxlPe activity of SxlPe0.4kbgalK and SxlPe0.8kb depend on XSE dose 
 
A) Numbers of viable Sxlf9 mutant females with reduced scute dose 
 
Crosses  w Sxlf9 ct / w Sxlf9 ct; TG/TG ×  scM6 w Sxlf9 ct /Y; +/+ 
Numerical data represent percentage of female viability. Numerical data in parenthesis represent 
the number of viable females.  
The number of sibling brothers from the cross were used as reference. 
 
B) Numbers of viable Sxlf9 mutant females with reduced runt dose 
  
Crosses  w Sxlf9 ct / w Sxlf9 ct; TG/TG ×  w Sxlf9 ct runt3 f /Ymal+; +/+ 
Numerical data represent percentage of female viability. Numerical data in parenthesis represent 
the number of viable females.  
The number of sibling brothers from the cross were used as reference. 
*The >100% female viability in larger deletion constructs reflect the reduced viability of w Sxlf9 
ct / Ymal+ males. 
 
 
In contrast, SxlPe0.8kb-SxlTG and SxlPe0.4kbgalK-SxlTG were highly sensitive to reductions 
in XSE dose. Although, both were susceptible to reductions in XSE dose, SxlPe0.8kb was 
severely affected than the SxlPe0.4kbgalK construct. SxlPe0.8kb could not rescue female 
viability at all and the promoter activity was highly dependent on the dose of sc and runt. 
SxlPe0.4kbgalK construct rescued sc and runt mutants sparingly (Table 3.4), suggesting the 
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strength of the SxlPe0.4kbgalK promoter activity depends on the dose of scute and runt but 
still managed to be turned on in some embryos. 
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CHAPTER IV 
REGULATORY MODULE OF XSE BINDING SITES AT SxlPe 
 
The crucial decision of appropriate sexual choice is orchestrated by X signal sensing at 
SxlPe. XSE interactions at the cis regulatory elements present along SxlPe ensures proper 
activation of Sxl and sexual development. Functional validation of the known activator 
and repressor binding sites at SxlPe is key to understanding SxlPe regulation; from how 
the promoter senses XSE dose to how it responds by turning SxlPe on or leaving it off.  
Advancements in functional dissection of SxlPe promoter structure, however, have been 
held back by insufficient knowledge about the binding sites of the key regulator sisA, and 
also by the lack of a tool to accurately assay the effects of mutated cis regulatory elements 
in vivo. 
  
Using the Sxl transgene system, individual or combinatorial cis regulatory site mutants 
can be easily engineered so that their effects on SxlPe activity and female fly viability can 
be studied. The system enables us to characterize each binding site mutation by detailing 
the onset of transcription, monitoring its timing, and comparing SxlPe expression levels 
with respect to the endogenous Sxl. The idea is to decipher the role of specific 
characteristics of the binding site, such as their location or binding affinities on promoter 
strength and Sxl activation.  
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Central to Drosophila sex determination is the X chromosome counting mechanism 
governed by the primary determinants, the X-signaling elements [5, 7]. Two of these 
XSEs, Scute and SisA are the key indicators of the X-chromosome dose [39, 41]. The 
XSE, Upd is the activating ligand for the JAK-STAT pathway and in turn activates the 
maternal Stat92E transcription factor that binds SxlPe to activate transcription [43, 44, 
54]. Stat92E binds to three different sites at SxlPe but mutations in these sequences had 
relatively modest effects on SxlPe. Interestingly Stat92E function is dispensable for initial 
activation but is needed to maintain full expression through cycle 14 [54]. Although, Runt, 
encodes a transcription factor of the RUNX family, exerts its influence on SxlPe activation 
by antagonizing the repression of the maternally contributed co-repressor Groucho 
(Erickson, unpublished data).  
 
Genetic, expression evidence and sequence evidence supports direct interaction of SisA 
and Scute at SxlPe [41, 71]. Unfortunately, nothing is known about how SisA binds SxlPe 
which leaves a significant gap in our understanding.   The best understood XSE protein is 
Scute.  Scute is a class A bHLH protein that binds DNA as a heterodimer with maternally 
supplied Daughterless (Da) protein. Eleven Sc/Da binding sites have been identified at 
SxlPe [47].  It seemed befitting to begin exploring Scute binding to establish the validity 
of our transgenic system as well as to better characterize the specific roles of the known 
Sc/Da binding sites in SxlPe regulation. While XSE activators are the central determinants 
of sex, they are only part of the story at SxlPe. Zygotically and maternally expressed 
negative regulators, including the bHLH repressor Dpn and its corepressor Gro are 
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required to maintain sex specific regulation [10, 65, 69, 83]. Our lab, previously 
researched the contribution of Dpn to the sex specific regulation and identified three 
specific binding sites at which, Dpn interacted with SxlPe in vitro using SxlPe-lacZ 
transgenes [64]. Mutations in each site lead to ectopic lacZ expression in males, consistent 
with their negative regulatory role, but their quantitative importance could not be assessed 
[64]. 
 
This chapter details the regulatory functions of Sc/Da binding sites at SxlPe as well as 
those of the repressor, Dpn. Preliminary work on other activators: including maternally 
supplied Stat and Zelda are described in the chapter appendix (Appendix B).  
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Characterizing the cis interactions of Sc/Da at SxlPe  
Overview of Sc/Da binding at SxlPe 
Scute is a class A, bHLH transcription factor that heterodimerizes with the maternal 
daughterless (Da) and binds to SxlPe to activate transcription [47, 73]. Our lab showed 
that Sc/Da binds to 11 sites located within the 1.4kb promoter and that binding occurred 
at both canonical, "E-box", and non-canonical sequences. The specific sequence 
information of the Sc/Da binding sites is listed in Fig.4.1A. The arrangement of these 
Sc/Da sites along SxlPe is concentrated in two clusters, sites 1-6 are located within the 
400bp segment we now know to be necessary and sufficient for sex-specific expression of 
SxlPe. The others are located further upstream between 0.8kb and 1.1kb in the proposed 
promoter augmentation element as depicted in Fig. 4.1B.  Sc/Da exhibited a range of 
binding affinities to the various sites, with most exhibiting relatively low affinity binding. 
Sites 2, 3 and 8 were bound with intermediate affinities whereas site 7, the only 
symmetrical canonical E-Box, was the only site bound with high affinity [47].  
 
A mutational analysis using a variety of inactivating point mutations in the Sc/Da sites 
was carried out using SxlPe-lacZ fusions in embryos [47]. The binding sites mutants were 
characterized in the context of the 0.4kb, minimal SxlPe promoter in -390bp SxlPe-lacZ 
transgenes. Promoter activity exhibited differences between transgenic lines and also 
between different females within a mutant line. Despite this, a general consensus prevailed 
that no single site was critically important for SxlPe expression as each single site mutant 
analyzed retained sex-specific expression.  Some binding site mutations caused modest 
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reductions in expression levels but dramatic reductions in SxlPe-lacZ expression were 
observed only when multiple Sc/Da sites were mutated. Most important for the work 
described here is that mutations in non-canonical Sc/Da sites 1, and 4, and in the E-box 
containing site 3, resulted in slightly reduced lacZ expression compared to unmutated 
transgenes. [47].  
 
 
 
Fig. 4.1: Sc/Da binding sites at SxlPe 
A) The nature and consensus sequences of Sc/Da binding sites. B) Schematic representation of the 
Sc/Da binding sites along 1.4kb, proximal SxlPe.  
 
 
Creating Sxl transgenes carrying mutations in Sc/Da binding sites 
I used my Sxl transgene system to analyze the roles of the known Sc/Da binding sites in 
the context of a fully functional Sxl locus.  The experimental strategy was to create Sc/Da 
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site mutations in the Sxl-Eug-TG so that their genetic and molecular effects could be 
analyzed in detail. Specific sequence changes to disrupt the binding of Sc/Da for every 
targeted site were made using site directed mutagenesis [84, 85]. A PCR amplified 
fragment containing the sequence change was then incorporated into the Sxl-Eug 
transgene using galK recombineering. A variety of individual and combinatorial mutations 
in Sc/Da binding sites were successfully created. The sequence changes for each of the 
Sc/Da binding site analyzed are shown in Table 4.1.  
 
 
Table 4.1: Mutated sequences of Sc/Da binding sites 
 
Sc/Da site mutated Original sequence Mutated sequence 
Sc/Da 1- CACCTTG CGCTTTG 
Sc/Da 2- CAGCCG CTAGCG 
Sc/Da 3- CATCTG GTTCTG 
Sc/Da 1-2- 
CACCTTG CGCTTTG 
CAGCCG CTAGCG 
Sc/Da 1-4- 
CACCTTG CGCTTTG 
CACCTTG CTCGATG 
 
 
Sc/Da site 3, an E-box, is a powerful cis regulatory element for SxlPe activation 
Single site changes in Sc/Da binding sites 1, 2, and 3 were analyzed. Sc/Da site 1 had the 
smallest effect on SxlPe activity. A single copy of SxlTG carrying a Sc/Da 1 site mutation 
(Sc/Da 1-) effectively rescued both Sxlf1 and Sxl7B0 females to 77.9% and 73.1% 
respectively (Table 4.2).  The SxlPe activity was scrutinized further by in situ 
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hybridization performed on embryos, homozygous for Sc/Da 1-SxlPe-Sxl-Eug-TG using 
the D. eugracilis intron probe. I found that in spite of Sc/Da 1 being mutated, these 
embryos were able to turn on SxlPe in cycle 12 in all female embryos with defects first 
appearing in cycle 13. The majority of embryos examined in cycle 13 were 
indistinguishable from wild type, however, one-third exhibited a non-uniform pattern of 
SxlPe expression.  
 
The range of non-uniform expression pattern observed in the Sc/Da binding site mutant 
embryos varied greatly and describing them was challenging. To better explain the 
different expression phenotypes observed, I classified them into five categories and used 
this as a comparison standard while describing the mutant phenotypes. (Each of the 
category is described in detail in Table 4.3 and the corresponding images for the categories 
are included in Appendix B). Classifying SxlPe expression into categories were primarily 
based on the estimated percentage of expressing nuclei. The staining intensity too 
contributed to the difference in expression but comparing intensity levels just by the naked 
eye was not reliable, making it unsuitable to be used as a main standard when categorizing. 
Simply using terms like high/medium/low SxlPe expression is misleading as it is more 
commonly referred to staining level rather than the expression pattern. Therefore, the term 
SxlPe activity was adopted to describe each category. 
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Table 4.2: Mutations in Sc/Da binding site affected female sex specificity 
A) Viability of Sxlf1/ Sxlf1 females with transgenes carrying Sc/Da binding site mutations 
 
 
Crosses  y w cm Sxlf1 ct/Binsincy; +/+ ×  y w cm Sxlf1 ct /Y; TG/+ 
Numerical data represent percentage of female viability. Numerical data in parenthesis represent 
the number of viable females. The Sxlf1/ Sxlf1 sibling females without transgenes were used as 
reference. 
 
 
B) Viability of Sxl7BO/Sxl7BO females with transgenes carrying Sc/Da binding site 
mutations 
 
 
Crosses  y pn w Sxl7BO/Binsincy; +/+ ×  y pn w Sxl7BO/Y; TG/+ 
Numerical data represent percentage of female viability. Numerical data in parenthesis represent 
the number of viable females. The Sxl7BO/ Sxl7BO sibling females without transgenes were used as 
reference. 
 
 
The non-uniform expression observed in cycle 13 Sc/Da 1- females exhibited around  
50% or more nuclei expressing SxlPe (categorized as moderately affected SxlPe activity 
or slightly affected activity), with still noticeable number of nuclei devoid of SxlPe 
expression. When advanced to cycle 14, all the embryos mimicked wild type expression 
(Fig. 4.2B). The wild type activity seen in cycle 14 likely explains why Sc/Da site 1 
mutants exhibited such high female viability in genetic complementation tests. What is 
perhaps surprising is that we could not identify cycle 14 embryos with defects that might 
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explain why 1/4 of them failed to rescue Sxl mutants. One possibility is that the failure of 
some cycle 13 female embryos to fully activate SxlPe in all nuclei, caused the reductions 
in female viability.  A second possibility, is that the two partially defective promoters 
interacted in trans to facilitate promoter activation. As discussed below in the context of 
Dpn binding site mutations, I have obtained evidence that active SxlPe promoters can 
exhibit transvection like effects that has been observed with transgenes in several systems.    
 
In contrast to Sc/Da site 1, a mutation in Sc/Da site 2 (Sc/Da 2-) had a significant effect 
on SxlPe activity. One copy of the Sc/Da 2- SxlPe-Eug-TG rescued some Sxlf1 and Sxl7bO 
females but the percentage of female viability was only 32.2% and 39% (Table 4.2). To 
better understand why the Sc/Da2- mutants were unable to strongly rescue the Sxl null 
alleles, I analyzed expression using in situ hybridization. SxlPe activity in Sc/Da 2- 
mutants and wild type was indistinguishable in cycle 12. In cycles 13 and 14, however, 
there were obvious differences among the expressing embryos. Approximately 30% of 
cycle 13 female embryos (number of embryos observed in each cycle is listed in Appendix 
B) had a wild-type expression pattern shown with paired darkly stained nuclear dots in 
every nucleus.  This wild-type pattern appeared to be retained through cycle 14 where I 
also observed that 30% of embryos appeared to be stained as the wild-type. The majority 
of embryos, however, had reduced SxlPe activity in both cycles 13 and 14.  SxlPe activity 
were judged to range from strongly affected (less than 50% of the nuclei expressing with 
faint nuclear dots) to moderately or slightly affected activity during cycle 13 (Fig. 4.2C).  
In cycle 14, few expressers with strongly affected activity were observed, instead almost 
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all of the expressing embryos showed moderately or slightly affected SxlPe activity. The 
strong correspondence between the viability tests and expression pattern from the 
transgenes suggest that only those embryos which are able to achieve wild-type or near 
wild-type activity survive, whereas those with defects in cycles 13 and 14 fail to fully 
engage Sxl expression. 
 
 
Table 4.3: Phenotypic categories of SxlPe activity in Sc/Da binding site mutants 
Phenotypic categories  
Percentage of 
nuclei 
expressing 
Description 
Severely affected 
activity < 30% 
SxlPe activity is observed in a small fraction 
(<30%) of nuclei. Majority of the expressing 
nuclei contain only one very faint nuclear dot. 
Strongly affected 
activity 30%-50% 
SxlPe activity is present in less than half of the 
nuclei. Expressing nuclei contain one or two 
faintly stained nuclear dots. 
Moderately affected 
activity ~ 50% 
SxlPe activity is observed in around 50% or 
slightly more than 50% of the nuclei. 
Expressing nuclei contain one or two nuclear 
dots that are stained slightly lighter than 
wildtype. 
Slightly affected 
activity >70% 
SxlPe activity is detected in most (>70%) 
nuclei, although small patches of non-
expressing nuclei still exist. Majority of the 
expressing nuclei contain two nuclear dots. 
Wild-type activity* 100% Embryos exhibit uniform expression pattern, with every nucleus expressing two nuclear dots. 
 
* Wild type activity means the transgenes mimicked endogenous SxlPe expression with respect 
to all nuclei expressing two nuclear dots but does not necessarily reflect the staining intensity. 
The staining intensity of the nuclear dots (as seen in 100X) sometimes appeared slightly weaker 
than the ones observed in Sxl-Eug-TG (control) embryos. Staining differences however are more 
prominent with respect to the overall staining of embryos. A possible reason for lower staining 
intensity is that mutants might reach the uniform expression pattern slightly later than wild-type, 
leaving less time for transcripts to accumulate and subsequently resulting in lighter staining.  
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Fig. 4.2: In situ hybridization of Sc/Da 1-SxlPe and Sc/Da 2-SxlPe transgenic lines 
Nuclear dots represent nascent SxlPe transcripts. Surface views of embryos were shown in both 
20X and 100X. 100X pictures were taken at the center of the embryos. A) Sxl-Eug-TG female 
embryos exhibited a uniform wild type expression, with two nuclear dots present in every nucleus. 
B) One-third of Sc/Da 1-SxlPe females had reduced SxlPe expression during cycle 13. C) SxlPe 
expression in Sc/Da 2-SxlPe females varied between embryos in both cycle 13 and early cycle 14.  
 
 
In contrast to what had been reported for SxlPe-lacZ transgenes, mutations in Sc/Da site 3 
(Sc/Da 3-) had a severe effect on SxlPe function. A single copy of the transgene carrying 
Sc/Da 3- could barely rescue Sxlf1 or Sxl7bO females as evidenced by 1.3% and 7.7% 
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viability respectively (Table 4.2). In situ hybridization of the Sc/Da 3- mutants provided 
several insights.  SxlPe expression was detected in occasional nuclei at cycle 12, in 10% 
of the total embryos. In cycle 13, about half (44%) of the embryos showed some kind of 
SxlPe expression although, most of them had severely affected SxlPe activity with only a 
fraction of nuclei (10-30%) exhibiting faintly stained dots (Fig. 4.3B).  
 
 
 
Fig. 4.3: In situ hybridization of Sc/Da 3-SxlPe transgenic lines 
Nuclear dots represent nascent SxlPe transcripts. Surface views of embryos were shown in both 
20X and 100X. 100X pictures were taken at the center of the embryos unless indicated.  
A) Sxl-Eug-TG female embryos exhibited a uniform wild type expression. B) Sc/Da 3-SxlPe 
females had severely affected SxlPe activity. Squares indicated the regions where 100X pictures 
were taken. 
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The SxlPe activity increased in cycle 14 with half of the female embryos showing 
moderately affected activity. The other half remained to be severely or strongly affected.  
Notably none of the embryos showed a uniform wild-type expression pattern (Fig. 4.3B). 
The in situ hybridization experiments explain why Sc/Da 3- transgenes fail to rescue Sxl 
null mutations, but they offer no clear explanation of the occasional female that survived. 
It may be the case that the most strongly expressing females produced sufficient SXL 
protein to stably activate maintenance expression of Sxl. If so, it suggests that the diffusion 
of Sxl mRNA or protein in the syncytial embryos led to the activation of Sxl in more nuclei 
than actually activated SxlPe. Alternatively, we may not have sampled enough embryos 
to have identified those with near wild-type expression pattern.  
 
A striking feature observed in the Sc/Da 3- line was related to the pattern of SxlPe 
expression. The Sc/Da 3- exhibited a strong regional bias in promoter activation.  Staining 
appeared stronger in terms of nuclear dot intensity and in the proportion of expressing 
nuclei, in the posterior of the embryos. We have no obvious explanation for this regional 
variation, but it is clear that Sc/Da 3- mutation effectively eliminates SxlPe expression in 
the central region of the embryo.  My results with Sc/Da site 3 are in direct conflict with 
those reported earlier from our lab and Paul Schedl's lab, using SxlPe-lacZ transgenes.  We 
have no clear explanation for why Sc/Da 3-  mutations had only a minimal effect in the 
context of 0.4 kb SxlPe-lacZ while nearly eliminating promoter activity in full length 
transgenes.  Regardless, these findings offer a cautionary tale about relying on results 
obtained only with minimal promoter/enhancer lacZ fusions.  
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Combinatorial Sc/Da mutants do not necessarily eliminate SxlPe expression 
In experiments with SxlPe-lacZ fusions, mutations of two or more Sc/Da sites typically 
eliminated SxlPe expression.  I tested two Sc/Da binding site double mutants, Sc/Da 1-2- 
and Sc/Da 1-4- and found that neither combination had as strong an effect as Sc/Da 3-, the 
E-box mutation alone.  Each combination, however, had a profound effect on SxlPe 
activity that seemed to reflect additive, rather than synergistic effects of the mutated Sc/Da 
sites. 
 
Sc/Da 1-2- for example, poorly complemented homozygous Sxl7BO, and Sxlf1 (9% and 25% 
female viability respectively) (Table 4.4), but that represents only a slight worsening of 
the effects of Sc/Da 2- mutation alone (Table 4.2). (Exact results of complementation tests 
with Sxl7BO and Sxlf1 differed in every case with rescue of Sxlf1 always being less effective.  
We do not know the reason although sex determination is known to be highly sensitive to 
genetic background effects.  One speculative possibility is that Sxlf1 might have a small 
dominant negative effect if its aberrantly spliced pre-mRNAs interfered somehow with a 
functional Sxl allele in the same cell.  A problem the deletion mutant Df(1)Sxlf7bO would 
not share.) 
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Table 4.4: Combinatorial Sc/Da binding site mutations retained some SxlPe activity 
A) Viability of Sxlf1/ Sxlf1 females with transgenes carrying Sc/Da binding site mutations 
 
Crosses  y w cm Sxlf1 ct/Binsincy; +/+ ×  y w cm Sxlf1 ct /Y; TG/+ 
Numerical data represent percentage of female viability. Numerical data in parenthesis represent 
the number of viable females. The Sxlf1/ Sxlf1 sibling females without transgenes were used as 
reference. 
 
B) Viability of Sxl7BO/Sxl7BO females with transgenes carrying Sc/Da binding site 
mutations 
 
Crosses  y pn w Sxl7BO/Binsincy; +/+ ×  y pn w Sxl7BO/Y; TG/+ 
Numerical data represent percentage of female viability. Numerical data in parenthesis represent 
the number of viable females. The Sxl7BO/ Sxl7BO sibling females without transgenes were used as 
reference. 
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Fig. 4.4: In situ hybridization of Sc/Da 1-2-SxlPe and Sc/Da 1-4-SxlPe transgenic 
lines 
Nuclear dots represent nascent SxlPe transcripts. Surface views of embryos were shown in both 
20X and 100X. 100X pictures were taken at the center of the embryos unless indicated. A) Sxl-
Eug-TG female embryos exhibited a uniform wild type expression. B) All Sc/Da 1-2-SxlPe females 
had reduced SxlPe expression. Squares indicated the regions where 100X pictures were taken. C) 
50% and 88% Sc/Da 1-4-SxlPe females reached wildtype expression at cycle 13 and early cycle 
14, respectively. 
 
 
I tested the effects of Sc/Da site 4 in combination with Sc/Da site 1 because the Sc/Da 4- 
mutations in the context of 0.4kb SxlPe-lacZ transgenes appeared to have similar but 
stronger effects than observed with Sc/Da 2- mutants [47]. Despite, Sc/Da 1-4- having two 
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Sc/Da sites mutated, its effects were only slightly more severe than Sc/Da 1- alone.  It had 
a moderate effect on SxlPe as percentage of female viability ranged from a 62.1% seen 
with Sxl7BO complementation test to a 34.2% seen with Sxlf1 (Table 4.4). The effect did not 
seem as severe as Sc/Da 1-2- naturally because it was essentially better than Sc/Da 2- alone. 
The in situ hybridization results too verified that the SxlPe expression was far better than 
the Sc/Da 2-.  Half of the cycle 13, Sc/Da 1-4-  female embryos reached wild-type activity 
and most of cycle 14 embryos (88%) showed wild-type SxlPe activity with only a few 
exhibiting mutant expression patterns (Fig. 4.4C). Certainly, the SxlPe activity or the 
viability data observed here were lesser compared to the individual Sc/Da 1- mutants but 
Sc/Da 1-4- being only a slightly stronger mutant than Sc/Da 1- revealed that Sc/Da site 4 
is the weakest SxlPe cis-regulator characterized thus far.  
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Characterizing repressor binding sites at SxlPe  
Overview of Dpn binding at SxlPe 
Dpn, as a member of the Hairy-Enhancer of split, HES family of bHLH repressors, binds 
to the E-box sequence CACGTG and a related sequence CACGCG [64, 65, 86-89]. The 
latter appears to represent the optimal binding sequence for Dpn and its relatives. The 
three known Dpn binding sites at SxlPe promoter are clustered within 200bp of the 
transcription start site and the exact location of the sites are specified in the Fig. 4.5. Dpn 
binding sites 1, 2 are canonical high-affinity CACGCG sequences whereas site 3 is non-
canonical and of lower affinity [64, 70, 90].  
 
 
 
 
Fig. 4.5: Dpn binding sites at SxlPe 
Schematic representation of the Dpn binding sites along the 400bp, proximal SxlPe. The 
corresponding binding site sequences are capitalized.  
 
 
Experiments carried out in our lab using 1.4 kb SxlPe-lacZ transgenes to study the various 
Dpn site mutants showed that mutated Dpn sites 1,2, or 3 led to ectopic SxlPe-lacZ 
expression in male embryos but appeared to have little effect on expression in females 
[64].  I note that the Schedl lab reported different results in the context of 0.4kb SxlPe-
-400
TATA
+1
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lacZ lines.  There they found that double mutations affecting canonical Dpn sites 1 and 2 
did not lead to ectopic expression in males and actually reduced lacZ activity in females.  
They attributed this to the binding sites being recognized both by Dpn and the postively-
acting Myc transcription factor [56].  
 
Creating Sxl transgenes carrying mutations in Dpn binding sites 
To use the Sxl transgene system to perform the mutational analysis of Dpn binding sites, 
the experimental transgene, Sxl-Eug-TG was modified to carry the desired binding site 
mutation. The experimental procedure followed was the same as used to create Sxl 
transgenes carrying mutations in Sc/Da binding sites (described earlier in this chapter).  
The Dpn binding site mutations used are shown in (Table 4.5).  
 
 
Table 4.5: Mutated sequences of Dpn binding sites 
Dpn sites mutated Original sequence Mutated sequence 
Dpn 1- CACGCG CACTGG 
Dpn 2- CACGCG CTCGAG 
Dpn 3- CACACT CACCCT 
Dpn 1-2- 
CACGCG CACTGG 
CACGCG CTCGAG 
Dpn 1-3- 
CACGCG CACTGG 
CACACT CACCCT 
Dpn 1-2-3- 
CACGCG CACTGG 
CACGCG CTCGAG 
CACACT CACCCT 
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Mutations in Dpn binding sites cause male lethality 
Several genetic tests were carried out with the SxlTG carrying the Dpn sites. The first were 
genetic complementation tests.  Complementation tests with Sxlf9, Sxlf1 and Sxl7bO showed, 
as expected that mutating the Dpn repressor binding sites did not adversely affect SxlPe 
expression in females as a single copy of each fully complemented the Sxl mutations.  
Reciprocally, mutations in the Dpn sites were expected to exhibit male-lethal effects due 
to constitutive expression of SxlPe in XY animals.  I found that was indeed the case; 
however, there were dramatic difference in the strengths of the lethal effects observed.  
 
Genetic analysis of the effects of transgenic Dpn site mutations in males is complicated 
by Sxl autoregulation. A wild-type male carrying a single Dpn mutant transgene for 
example, should express the early form of Sxl protein exclusively from the transgene; 
however, the early Sxl protein will facilitate the splicing of SxlPm-derived maintenance 
transcripts from both the transgenic and endogenous Sxl loci.  Normal males thus represent 
a sensitized system that should amplify the effects of Dpn site mutant transgenes. To 
simply compare between mutants, I asked whether the Dpn site mutant transgenes in either 
one or two copies exhibited lethal effects in Sxlf7bO males, who are deleted for the 
endogenous Sxl locus.  The results indicated that each mutant transgene expressed SxlPe 
and killed males but that the efficiency of killing varied. In single copy, none of the Dpn 
site mutants, including the Dpn 1-2-3-, was fully lethal to males (Table 4.6B), indicating 
that the level of expression was too low to reliably engage the autoregulatory loop.  
However, when two copies were present strong lethal effects were observed for all Dpn 
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site mutants except Dpn 1-.  In agreement with the analysis of Lu et al. [64] the non-
canonical Dpn site 3- mutations had the strongest effects on viability with males being 
barely able to tolerate two copies of Dpn 3- mutant or Dpn 1-2-3- combination (Table 4.6B).  
The Dpn 1- mutants exhibited the weakest effect on its own, 57% male viability with two 
copies (Table 4.6B), but curiously the Dpn site 1- change tended to ameliorate the lethal 
effects of Dpn 2- and Dpn 3- mutations.  This may reflect the hypothesized dual nature 
[56] of the canonical sites as binding both activators and repressors.  I also examined the 
effects of the Dpn site mutant transgenes in males carrying an intact copy of the 
endogenous Sxl locus (Table 4.6A) and or the early defective, but late effective, allele Sxlf9 
(Appendix B). While the exact numbers differed, the same general trends were observed.  
Of note was the finding that the Dpn 1-2-3- transgene could never be recovered in males 
carrying two copies of Sxl, indicating that this combination leads to the greatest level of 
ectopic SxlPe expression.    
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Table 4.6: Dpn binding site mutations reduced male viability 
A) Lethality test in wildtype males carrying DpnMSxlPe-SxlTG 
 
 
 
Crosses +/+; TG/+ × +/Y; TG/+ 
Numerical data represent percentage of male viability. Numerical data in parenthesis represent 
the number of viable males. The +/Y sibling males without transgenes were used as reference. 
 
B) Lethality test in Sxl7BO males carrying DpnMSxlPe-SxlTG 
 
 
 
Crosses  y pn w Sxl7BO; TG/+ ×  y pn w Sxl7BO/Binsincy /Y; TG/+ 
Numerical data represent percentage of male viability. Numerical data in parenthesis represent 
the number of viable males. The Sxl7BO/ Y sibling males without transgenes were used as 
reference. 
 
 
Dpn binding sites mutation induced ectopic SxlPe expression in males and provided 
evidence of transvection between transgenic alleles 
To examine the effect of Dpn binding site mutations on SxlPe expression, in situ 
hybridization was performed on the progeny from Sxl7BO mothers homozygous for 
DpnMSxlPe-Eug-TG and Sxl7BO fathers homozygous for Sxl-Persi-TG. The SxlPe activity 
from both transgenes were detected by using probes specific for each allele. 
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Fig. 4.6: Ectopic SxlPe expression in DpnMSxlPe transgene carrying Sxl7BO male 
(XY) embryos  
Nuclear dots represent nascent SxlPe transcripts. Surface views of embryos were shown in both 
20X and 100X. 100X pictures were taken at the center of the embryos. All DpnMSxlPe transgenic 
lines showed ectopic SxlPe expression. 
 
 
All transgenic lines carrying Dpn binding site mutations exhibited ectopic SxlPe 
expression in at least half of the male embryos during cycle 13 and early cycle 14 (Fig. 
4.6).  Dpn 1- initiated a low level, SxlPe activity in a small fraction of nuclei in 50% of the 
male embryos. Typically, the ectopic expression for the Dpn 1- mutation was characterized 
by the presence of a faintly stained nuclear dot in expressing nuclei.  This apparent low-
level expression is consistent with the minimal male lethal effects observed with the      
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Dpn 1- mutants (Table 4.6 and Appendix B) and shows that XY embryos can establish and 
maintain their male identity with low-level of SxlPe.  
 
The Dpn 2- mutant showed a similar ectopic expression pattern to Dpn 1-.  However, the 
percentage of male embryos with ectopic expression, the number of nuclei expressing, and 
the staining intensity were all slightly higher compared to Dpn 1-. Since, the Dpn 2- 
mutations resulted in higher male lethality than Dpn 1- (Table 4.6B), this indicates that the 
level of ectopic SxlPe activity observed in Dpn 2- often exceeds the threshold level needed 
to stably activate Sxl.  
 
Consistent with the strong male-lethal effects observed, the Dpn 3- transgene, induced 
ectopic SxlPe expression in a greater number of male embryos compared to Dpn 1- or Dpn 
2-.  During early cycle 14, the weakest expressing one third Dpn 3- embryos showed non-
uniform ectopic expression with both the percentage of nuclei expressing and staining 
intensity being higher than the other canonical Dpn 1-  and Dpn 2- mutations (Fig. 4.6 and 
4.7).  The rest two thirds of the Dpn 3- embryos possessed a strongly stained nuclear dot 
in every nucleus. Remarkably these embryos strongly resembled XX females as they 
usually expressed two dots in each nucleus.  This indicates that many XY embryos were 
able to activate SxlPe from both the constitutive mutant transgene and normally inactive 
wild-type transgene, suggesting the exciting possibility that the SxlPe promoter may 
exhibit a transvection like mechanism whereby one active promoter facilitates the 
activation of the other allele [91-93]. I will discuss this finding in more detail below.  
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Comparing the two combinatorial mutants, Dpn 1-2- and Dpn 1-3-, the latter showed a 
higher SxlPe activity in male embryos. Expression in the Dpn 1-2- line closely resembled 
that seen in the Dpn 2- single mutant consistent with Dpn 1- mediating only a weak 
repressive effect.  Likewise, embryos bearing the Dpn 1-3- transgene resembled those 
carrying the single strong Dpn 3- transgene with the Dpn 1-3-  appearing to express in an 
even greater number of nuclei than the Dpn 3-  single mutant. The Dpn 1-3- combination 
also exhibited evidence of transvection, as many nuclei expressed both the Dpn 1-3- 
experimental transgene and the control (Fig. 4.6 and 4.7).   
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Fig 4.7: FISH image depicting the ectopic SxlPe expression in DpnMSxlPe transgene 
carrying Sxl7BO male (XY) embryos  
Nuclei were stained with DAPI and shown in blue. Nuclear dots (green) represent SxlPe transcripts 
from DpnMSxlPe-Eug-TG. Nuclear dots (red) represent SxlPe transcripts from Sxl-Persi-TG.  
A) Magnified confocal images of cycle 13 embryos heterozygous for Sxl-Persi-TG and       
DpnMSxlPe-Eug-TG (experimental). All DpnMSxlPe transgenic lines showed ectopic SxlPe 
expression. B) Enlarged single nucleus from Dpn1-3- image show both constitutive SxlPe 
expression from the experimental transgene (green) and trans-activated SxlPe expression 
from the control transgene (red). 
 
 
Evidence that a constitutive SxlPe promoter can activate a wild-type SxlPe promoter 
in trans   
My in situ hybridization analysis provided the surprising finding that the Dpn site mutant 
lines with the strongest SxlPe expression appeared also to activate the control Sxl+ 
transgenes, which are normally completely inactive in male embryos. More direct 
evidence for transactivation by SxlPe, was obtained using fluorescent in situ hybridization 
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(FISH) to distinguish between transcripts initiated from the Dpn site mutant bearing 
experimental transgenes and the wild-type controls. When I examined the Dpn 1-, Dpn 2-
, and Dpn 1-2- transgenes, I found that expressing nuclei in males usually expressed SxlPe 
only the Dpn 1-, Dpn 2-, or Dpn 1-2- bearing transgene as evidenced by the presence of a 
single, green colored nuclear dot (Fig 4.7). Occasionally, however, a second red nuclear 
dot was seen indicating that the control Sxl+ transgene was also expressed.  When I 
examined the more strongly expressing Dpn 3- and Dpn 1-3- transgenes, I found that the 
majority of nuclei that expressed the Dpn mutant transgenes (green dots) also expressed 
the control transgene (red dots) (Fig. 4.7).   
 
While my data strongly suggest that some form of transactivation by SxlPe occurs, we 
have no information as to mechanism.  It could be the case that the early Sxl protein has 
an unexpected transcriptional autoregulatory function. Alternatively, transactivation 
might involve a transient chromosomal pairing akin to seen in classical transvection [93-
96], or it could reflect the production of non-coding RNAs [97] that act in trans to facilitate 
expression.  Regardless of the mechanism, the possibility that one activated SxlPe 
facilitates the activation of the second copy, suggests the exciting possibility that the fly 
exploits this phenomenon as a means to facilitate rapid and efficient engagement of Sxl 
expression.  Such a system may well be an elegant solution to the fundamental problem 
of ensuring that the response to XSE signal remains female-specific.  
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CHAPTER V 
CONCLUSIONS AND METHODS 
 
Sxl transgene system in analyzing SxlPe activity 
The goal of my thesis research was to develop a novel transgenic system that would allow 
us to probe the details of Sxl regulation in the fly.  The system was designed to allow easy 
introduction of genetic alterations in vitro, and then transform into flies so that both the 
tools of genetic analysis and in situ hybridization could be used to analyze the production 
of Sxl nascent transcripts and mature mRNAs. My focus was on the regulation of the 
transiently acting promoter, SxlPe which functions as a dose-sensitive genetic switch that 
measures X chromosome dose to determine the sexual fate[6, 8, 38]. Previous work on 
SxlPe employed promoter-lacZ fusions that provided insight into the modular structure of 
SxlPe and in the importance of several binding sites for regulators of X chromosome dose 
[8-10, 47, 59, 64, 71]. What SxlPe-lacZ fusions could not do was to allow us to fully 
employ the sophisticated classical genetic tools available to study sex determination, nor 
could they reliably identify nascent SxlPe transcripts, a tool that has led to considerable 
insight into the mechanism of primary sex determination [9, 64, 98].  
 
The Sxl transgene system I developed answered how the mutations in the Sxl loci affected 
the biology of the fly and provided a true quantitative understanding of the female flies 
surviving, unlike just monitoring SxlPe-lacZ expression which were often not too 
conclusive. The female and male viability data obtained are very accurate and they were 
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similar when repeated with the same transgenic line or compared with other transgenic 
lines carrying the exact same mutation. This allowed reliable and uniform comparisons 
among transgenic lines while analyzing the different SxlPe mutants. 
  
Monitoring SxlPe activity as nascent nuclear dots and mature transcripts in the Sxl 
transgene system made the system reliable for predicting onset of transcription, identify 
spatial-temporal patterns of expression and compare SxlPe expression between various 
SxlPe mutants. The pool of data obtained by using the Sxl system to study promoter 
deletions and binding sites mutations, deepened our understanding of SxlPe and gathered 
new insights that were either missed or unidentifiable in earlier experiments involving 
SxlPe-lacZ model.  
 
With respect to SxlPe activity, the transgenes I developed appear to precisely mimic the 
timing, levels, and functions of the endogenous Sxl locus.  The only noticeable difference 
being that the nuclear dots that mark the nascent transcripts in the embryonic nuclei were 
in different nuclear locations in the transgenes than for the endogenous Sxl gene. The 
nuclear dots from the transgenic copies also appear to be farther apart than with the 
endogenous locus [9, 10, 54, 98].  These differences almost certainly stem from the Sxl 
transgene being integrated in chromosome 2 rather than in the X chromosome. 
 
Our initial plan was to create "marked" transgenes carrying homologous segments of DNA 
from different Drosophila species with the expectation that this would allow allele-
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specific detection via in situ hybridization while fully preserving genetic function.  What 
we discovered, however, was that only sequences from the most closely related species 
examined fully preserved all aspects of Sxl regulation.  This created a problem for the 
detection of transgenic Sxl transcripts because of cross-hybridization between the D. 
eugracilis probe and the endogenous melanogaster gene.  I solved this problem by 
developing higher stringency in situ hybridization conditions that ensure that the D. 
eugracilis probe only detects the SxlPe signal from the Sxl-Eug-TG. As a result, the SxlPe 
activity can now be successfully monitored in strains carrying the Sxl7B0 deletion or in 
those with wild type Sxl.  
 
The sequences that I swapped between species stretched from exons E1 through L2 and 
thus could in theory affect SxlPe transcripts, which splice from E1 to L4 directly, or SxlPm 
transcripts which splice from the upstream L1 exon to L2 to L4 (or to the translation 
terminating L3 exon in males.)  Exon E1 to L2 sequences from the closely related species, 
D. erecta and D. eugracilis, provided both early (i.e. establishment) and late 
(maintenance) functions.  In contrast E1-L2 sequences from the more distant (~20-30 
million years) D. persimilis and D. pseudoobscura provided early function but appeared 
to be defective in producing the maintenance Sxl function.  Swapping in the E1-L2 
segment from the even more distant D. virilis eliminated both the ability to provide early 
and late Sxl functions.  These findings suggest that the sequences can likely affect the 
splicing of the early (establishment) and late (maintenance) forms of Sxl mRNA and thus 
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offer a possible experimental window into better understanding the still mysterious means 
by which SxlPe transcripts skip exons L2 and L3 [99]. 
 
It was our plan from the beginning to develop the means to quantify SxlPe activity using 
fluorescent in situ hybridization and automated microscopy.  Such a system should 
recognize and be able to count the number of nuclei expressing one, two, or no nuclear 
dots and to measure the intensities of the fluorescent signals. Automation of this process 
would greatly facilitate the analysis of cis-acting SxlPe mutations.  It would overcome the 
laborious process of counting each and every nucleus in single embryos and that it should 
provide quantitative or semi-quantitative information as to expression thus replacing the 
visual biases of the experimenter. Unfortunately, I was unable to fully develop this aspect 
of the transgene system.  Stumbling blocks included the need to modify existing software 
that was designed for different imaging systems and biological measures [100-103], as 
well as issues of signal detection and background. The later represents a substantial 
obstacle. When we analyzed strong SxlPe mutants, for example, it proved very difficult to 
reliable detect and clearly identify the faint dots expressed from the mutant allele from the 
strong dots produced by the control allele. These dots could not be detected by the program 
reliably always and was a problem. With the dedicated efforts of Dr. Stan Vitha of the 
Texas A&M Microscopy and Imaging Lab, I anticipate that the remaining problems will 
be solved and that this promising aspect of the transgenic technology will be made fully 
available in the near future. 
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Structure and regulatory role of SxlPe enhancer in Sxl activation 
My work on the SxlPe enhancers focused on defining the architecture of SxlPe to better 
understand the operation of the sex-determining switch.  A central question was to 
determine the DNA sequences both necessary and sufficient for SxlPe function.  
Transgenic reporter fusions between SxlPe deletions and lacZ provided useful information 
about functional segments of SxlPe [47, 64, 71] but the question of whether the functional 
elements identified could drive sufficient expression in their native context were 
unanswered. We approached this larger scale definition of SxlPe promoter and enhancer 
elements by testing the exact same promoter deletions previously examined [71]. Our 
findings served as a strong validation of most interpretations made by Estes et al. [71] and 
Yang et al [47] but also offered the surprising result that a minimal 400 bp segment that 
drives sex-specific expression in a patchy low-level expression pattern is actually 
sufficient to rescue flies defective for Sxl early function.  Summarizing the key findings, 
it appears that the SxlPe promoter/enhancer contains three structural elements.  A critical 
promoter proximal 400 bp region that drives female-specific SxlPe expression, and two 
more distal segments that appear to augment expression of SxlPe allowing it to be 
expressed strongly in all parts of the embryo. 
 
The augmentation functions of the SxlPe enhancers appear to map primarily in two 
segments: located approximately -1.4 to -3.0 kb upstream and from -0.8 to -1.4 kb 
upstream of the SxlPe start.  The segment from -0.8 to -1.4 kb appears to play the most 
important augmentation function as transgenes containing it plus the minimal sex-specific 
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promoter express SxlPe nearly as strongly as wild-type transgenes and in nearly every 
embryonic nucleus.  Such transgenes provide sufficient early Sxl function to fully rescue 
the viability of Sxlf9/Sxlf1 females, the most defective genetic combination possible to 
analyze.  Suggestively, the segment from -0.8 to -1.1 kb contains evolutionary conserved 
sequences that include two canonical binding sites for the XSE activator Sc/Da.  As 
discussed in Chapter 3, we cannot subdivide the -1.4 to -0.8 kb segment further even 
though -1.1 kb transgenes do not fully rescue Sxlf9/Sxlf1 females and contained fewer nuclei 
that express SxlPe than the longer transgenes.  The differences could indeed reflect the 
presence of positive regulatory elements between -1.1 and -1.4 kb.  However, the reduced 
expression could also reflect that the transgenic constructs alter the context of SxlPe by 
placing DNA normally located upstream of SxlPm adjacent to the regulatory elements of 
SxlPe.  If this upstream DNA partially silences the activity of the -1.1 kb, but not the -1.4 
kb, SxlPe transgene it could explain why the -1.1 kb version expresses less effectively.   
 
Transgenes that include the full segment to -3.0 kb fully rescue Sxlf9/Sxlf1 females and 
express SxlPe in every embryonic nucleus with the expression levels appearing 
indistinguishable from those of fully wild-type transgenes.  It seems reasonable to 
conclude then that the 3kb construct be considered as containing the entire SxlPe 
regulatory region. This non-coding upstream region diverges in sequence between 
Drosophila species; however, species as distant as D. eugracilis all carry a cluster of 3 
canonical Sc/Da binding sites suggesting that these XSE binding sites contribute to the 
augmentation function. 
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The minimal promoter region for SxlPe includes only the 0.4 kb immediately upstream of 
the promoter, as demonstrated by the ability of the 0.4kb galK SxlPe contruct to 
complement Sxlf9.  (We cannot exclude the possibility that sequences downstream also 
play a role in SxlPe regulation but there is no evidence suggesting this is the case.) The 
experiments of Estes et al [71] demonstrated the 0.4 kb region to be sufficient of sex-
specific on or off regulation, but this minimal promoter element expressed weakly and in 
a distinctly non-uniform pattern. Our more detailed expression analysis is consistent with 
earlier findings in that expression is weak and patchy, with a distinct anterior and posterior 
bias (Fig. 3.4).  My finding that the 0.4 kb construct successfully rescues most Sxlf9 
homozygotes and many Sxlf9/Sxlf1 females is surprising given the low-level non-uniform 
expression. This suggests that Sxl must be capable of being stably activated by locking in 
autoregulatory splicing in many more cells than SxlPe is active in. This likely reflects 
considerable cell non-autonomy of Sxl mRNA in the syncytial embryo. What is critically 
needed are estimates of when these cells and how many of them express Sxl protein. 
Unfortunately, our anti-SXL antibody no longer works and we have been unable to obtain 
a substitute that works effectively in the early embryo.   
 
Regardless of the precise details, the ability of the imperfectly expressing 0.4 kb SxlPe 
transgenes to provide sufficient early Sxl protein for viability has important implications 
for how the sex determining mechanism might have evolved. There is a tendency when 
examining a complicated process like X-counting to view its present day extreme 
efficiency as a prerequisite for function. Analysis of the deletion transgenes, however, 
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reveals that a considerable degree of messiness is compatible with biological function.  
This suggests that there may have been considerable freedom to experiment and improve 
the X-counting mechanism as it evolved. 
 
Do upstream sequences normally influence Sxl transcription? 
My discovery that the insertion of a 1.2 kb bacterial galK sequence upstream of the 0.4kb 
SxlPe promoter elevated Sxl expression demonstrated that the upstream sequences placed 
next to SxlPe in creating the deletions had an inhibitory effect on SxlPe activity.  The 
"silencing" sequences come from CG4615 the gene immediately upstream of Sxl.  CG4615 
is expressed maternally but does not appear to be expressed zygotically until at least the 
cellular blastoderm stage (Flybase, expression data).  This hints that the silencing observed 
may result from the artificial juxtaposition of inactive chromatin next to the permissive 
chromatin of SxlPe. This raises the question of whether this "silencing" might be part of a 
normal mechanism that helps keep SxlPm inactive until it is needed in cycle 14 [11]. One 
could test this idea by adding spacer DNA between SxlPm and CG4615, or by replacing 
CG4615 with an active gene, to see if SxlPm is activated earlier than normal. 
 
The roles of Sc/Da binding sites in regulating SxlPe 
Scute is quantitatively the strongest XSE and Sc/Da is a key regulator in SxlPe regulation 
[39, 41].  Past analysis with 0.4 kb SxlPe-lacZ transgenes suggested that SxlPe is regulated 
by multiple Sc/Da binding with no single site having a predominant effect or even a 
particularly strong effect. In striking contrast, my analysis revealed that two individual 
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Sc/Da binding sites had strong effects on SxlPe activation. Specifically, Sc/Da site 2- 
mutations had a significant effect on female viability and site Sc/Da site 3- mutations 
abolished SxlPe activity marking site 3 as the most critical regulatory site along SxlPe 
enhancer characterized. One possibility is its strength as a regulatory site reflects that it is 
the only canonical E-box in the proximal SxlPe enhancer, however, the in vitro binding 
affinity of Sc/Da for site 3 was no higher than that for site 2 [47] suggesting the reason for 
site 3 importance lies elsewhere. A reasonable possibility is that site 3 might be a 
nucleation site and that Sc/Da binding there may facilitate the recruitment and spreading 
of chromatin modifiers, which in turn increase the chromatin accessibility of the 
surrounding region and lead to the initiation of SxlPe.  
 
Such a role could come about if Sc/Da 3 were the most accessible site or the site where 
the activators begin to bind first at SxlPe. Suggestively two overlapping copies of the 
TAGteam sites that are bound by the pioneering transcription factor Zelda overlap with 
Sc/Da site 3. TAGteam sites are bound by Zelda before and during maternal-to-zygotic 
transition (MZT), to help initiate transcription of early developmental genes [58, 59, 104, 
105]. Although, the mechanism by which Zelda binding influences SxlPe activation is not 
established, Zelda binding could increase chromatin accessibility [61-63], rendering the 
Sc/Da site 3 to be one of the first accessible sites. I note that our analysis of the effects of 
Sc/Da site mutations are potentially complicated by the overlapping TAGteam sites.  The 
mutation in Sc/Da site 3 was carefully designed within the three base pairs of the hexamer 
binding site sequence that are not shared by the TAGteam doublet. Although, the 
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TAGteam doublet was not mutated, it is not certain whether modifications to a 
neighboring base pair changes Zelda binding. If it does, then the strong effect we observed 
could be the cumulative effect of the loss of two positively acting factors. I do note, 
however, that the TAGteam doublet was characterized as a weak regulatory sequence of 
SxlPe, and indeed it was the weakest among the rest of the TAGteam sites present at SxlPe 
[59]. This suggests that the strong effects we observed are mostly likely the result of 
altered Sc/Da binding to site 3.  
 
Although the exact mechanism of how Sc/Da site 3 regulates SxlPe activity is still not 
known, I successfully identified Sc/Da site 3 as a unique, key regulatory site, as mutating 
this single site completely eradicates SxlPe activity. The novel finding that Sc/Da site 3 is 
essential to ensure the sex-specificity of SxlPe enhances our understanding of how Sxl 
works as a genetic switch. 
 
Analysis of Dpn binding site mutations: repressor function and a possible 
transvection mechanism for X-signal amplification 
My analysis of the binding sites for Dpn, and related repressors at SxlPe, generally 
validated previous work using SxlPe-lacZ fusions [64] but revealed new details about the 
importance of individual repressor binding sites, and offered some support for the idea 
that some repressor binding sites may also bind activators [56]. 
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In agreement with earlier studies [64], the non-canonical, Dpn binding site 3 proved to 
have a powerful regulatory role than the closely juxtaposed canonical Dpn binding sites 1 
and 2. This was evidenced by the stronger male-lethal effects observed for transgenes 
carrying site 3 mutations compared to those with sites 1 or 2. We speculate that the 
importance of this site is not based on its non-canonical sequence per se but rather its 
location adjacent to a strong activator site Sc/Da site 2 and the nearby Sc/Da site 3 [47, 
64].  
 
The canonical, Dpn binding sites 1 and 2 have identical sequences [64, 70, 90] but their 
regulatory abilities appear to differ. Dpn site 2 appeared a stronger negative regulatory site 
in most assays than did Dpn site 1 (Table 4.6 and Appendix B) and there is no apparent 
reason for this. Although, Dpn site 1 is located exactly adjacent to Sc/Da site 1 [47, 64] 
and Dpn site 2 is adjacent to a TAGteam site [59, 104] and it is possible that the nature of 
activator site besides them maybe relevant to the difference in their regulatory effects. 
Alternatively, canonical Dpn binding sites are capable of low affinity binding in vitro to 
bHLH transcription factors like Myc, raising the possibility that the canonical sites have a 
dual nature at SxlPe [56]. If so, the male-lethal effects and ectopic male expression arising 
from the Dpn sites 1 and 2 transgenes suggest their repressive functions predominate. 
 
What is probably the most significant result from my work on the Dpn site mutations was 
completely unexpected and, indeed, came about because I included what seemed at the 
time an unneeded control.  I was analyzing the Dpn site mutant transgenes using FISH to 
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determine how much ectopic expression each was caused in males. The flies carried Sxl-
Eug-TG with Dpn site mutations and also a wild type control Sxl-Persi-TG.  Since the wild 
type transgene should be inactive in males there seemed no need to include the control D. 
persimilis probe but I did anyway. When I analyzed the embryos, I found the surprising 
result that SxlPe was often expressed from both SxlTG copies: the constitutive ones 
bearing the Dpn site mutations, and the wild type (Fig. 4.7). The conclusion is that, 
somehow, the active SxlPe activated the normally silent copy on the other chromosome. 
The obvious analogy is to transvection, the process, usually involving chromosome 
pairing, where one copy of an enhancer acts in trans to activate the other allele in trans 
[106]. Of course, other mechanisms are possible including, trans activation via expression 
of non-coding RNAs as well as the possibility that Sxl protein could be an autoregulatory 
transcription factor.  Regardless of the actual mechanism, the notion that once activated, 
one Sxl allele promotes the activation of the second allele in trans, has considerable appeal 
as a female-specific mechanism to amplify the value of the XSE signal.  
 
Given the novelty and potential importance of this "trans activation" phenomenon, it is 
important both to recognize that so far, we do not know if the phenomenon is limited to 
transgenic copies or if it applies to the native locus as well.  Transactivation via paired 
enhancers has been observed repeatedly in analysis of transgenes [106-108] but there are 
reasons to think that it may well apply to the endogenous Sxl locus. The most suggestive 
evidence comes from analysis of nascent transcripts as measured by nuclear dots.   
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The endogenous SxlPe is activated to low levels in nuclear cycle 12. It has been reported 
that some cycle 12 embryos have nuclei expressing zero, one, or two nuclear dots, which 
has been interpreted as evidence of independent activation of the alleles [98]. An important 
caveat to that conclusion is that when embryos are examined a few minutes later, in cycle 
13, every single nucleus expresses both alleles and this pattern continues through cycle 
14. This suggests the possibility that the observed pattern of SxlPe activation could also 
be explained if initial activation occurs independently on each chromosome, but that once 
a copy of SxlPe is fully active, it facilitates the expression of its homologous copy. This 
alterative would suggest that the likelihood that transactivation will occur depends on the 
level of expression from the transactivating promoter. This indeed appears to be the case. 
With the Dpn site mutants, there was a correlation between the strength of expression of 
the constitutive transgene and the ability to activate in trans (Fig. 4.7).  The weak Dpn site 
1 mutation barely transactived, the slightly stronger expressing Dpn site 2 mutant did so 
slightly more effectively, while the strongest mutant tested Dpn site 3, transactivated in 
nearly every nucleus. One important limitation on the analysis of nuclear dots up till now 
has been the reliance on the naked eye. It will be necessary in the future to accurately 
quantify the number of nuclei expressing one dot versus two-dots so that inferences can 
be drawn with confidence. My transgenic system is ideally suited to this. 
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Methods 
Fly stocks and genetic tests 
All flies were raised on medium containing yeast, cornmeal and molasses at 25 ◦C. All 
genetic tests were performed at 25 ◦C in uncrowded conditions on medium topped with 
yeast.  
 
Sxlf9, Sxlf1 and Sxl7bO lines were obtained from Bloomington Stock Center. Sxlf9, Sxlf1 and 
Sxl7bO alleles are homozygous female lethal. Sxlf9 affects the establishment of female 
identity [20, 80], Sxlf1 is a null allele that disrupts the maintenance of the sex determination 
pathway [109] and Sxl7bO is a null allele that deletes the entire Sxl transcription unit [78]. 
Complementation tests were conducted by bringing Sxl transgenes into homozygous Sxlf9, 
Sxlf1 and Sxl7bO background to examine the viability of these flies. +/Y; TG/+ flies were 
crossed with Sxlf9/Binsincy, Sxlf1/Binsincy and Sxl7bO/Binsincy virgin females. Progeny 
with the genotype Sxlf9/Y;TG/+, Sxlf1/ Y;TG/+ and Sxl7bO/ Y;TG/+ were picked and re-
crossed with Sxlf9/Binsincy, Sxlf1/Binsincy and Sxl7bO/Binsincy respectively. The progeny 
from this cross was counted and the viability percentage of Sxlf9/ Sxlf9;TG/+, Sxlf1/ 
Sxlf1;TG/+ and Sxl7bO/ Sxl7bO;TG/+ were calculated using their Sxlf9/Binsincy, 
Sxlf1/Binsincy and Sxl7bO/Binsincy sister siblings as reference. 
 
Generation of delPe-SxlTG 
The exact regions included in delPe-SxlTG constructs can be found in Estes et al [71]. The 
regions upstream and downstream of the deleted region were PCR amplified using 
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AccuPrime Pfx DNA polymerase (Invitrogen), followed by digestion and ligation. The 
ligated fragment was purified and then used to replace the corresponding wildtype SxlPe 
sequence in Pacman II vector via galK recombineering. 
 
Generation of binding site mutations 
The binding site mutations were generated by site-directed mutagenesis PCR using 
primers carrying the desired mutations. After PCR, the plasmid templates were removed 
by DpnI treatment and the linearized PCR fragments were re-circularized by ligation using 
Quick Ligation Kit (New England Biolabs Inc.). E.coli were transformed with the ligated 
products. Plasmids were isolated from the transformants and sequenced to confirm that 
they carried the mutation of interest. The mutation of interest generated were PCR 
amplified using AccuPrime Pfx DNA polymerase (Invitrogen) and the purified fragments 
were ready to be used in galK recombineering.  
 
galK recombineering 
The detailed protocol of galK recombinnering can be found at 
https://ncifrederick.cancer.gov/research/brb/protocol/protocol3_sw102_galk_v2.pdf. The 
following modifications were made to the original protocol. In the first step of galK 
recombineering protocol, E.coli galK was integrated into the Sxl-pacman II plasmid at the 
target region. The recombinant bacteria were selected on M9 agar medium with 0.2% 
galactose and on MacConkey indicator plate to select for galK positive pink colonies. In 
the second step, the PCR fragments carrying the specific deletions or mutations were used 
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to replace galK. The recombinant bacteria here were selected on M9 agar medium with 
0.2% 2-deoxy-galactose and re-selected on MacConkey indicator plate and the white 
colonies were selected as the positive recombinant. Positive recombinant plasmids were 
purified using PureLink HiPure Plasmid Midiprep Kit (Invitrogen) and confirmed by 
sequencing. 
 
Sxl transgenic flies 
To obtain transformants carrying the Sxl transgene system, the purified and confirmed Sxl-
pacman II plasmid constructs were injected into embryos containing attP docking site. All 
our plasmid constructs were integrated into the attP40 site on the second chromosome. 
The transgenic injection service was provided by BestGene Inc and Rainbow transgenic 
flies, Inc. 
 
In situ hybridization 
Whole mount embryo collection of 3 hour and 30 minutes were dechorionated in 50% 
bleach and fixed in 1XPBS, 50mM EGTA, 10% formaldehyde and heptane for 50 minutes. 
The detailed protocol of in situ is adapted from previous publication [42]. Hybridization 
was performed at 65 ºC. 
 
Templates for probes were generated by PCR amplification using forward primers and 
reverse primers with 5’ T7/T3 promoter sequence. In vitro transcription using 
MAXISCRIPT T3/T7 kit (Ambion) was performed to synthesize digoxygenin(dig) 
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labeled antisense RNA probes. Anti-dig antibody coupled with alkaline phosophatase 
(Roche) was used to detect the probe and embryos were stained with NBT/BCIP solution 
(Roche). DAPI staining was conducted to allow nuclei visualization by UV fluorescence. 
Embryos were mounted in 70% glycerol/PBS and staged based on nuclei number, shape 
and membrane furrows as described in previous publication [42]. 
 
Probe templates were made using the following primers: 
 
D. persimilis SxlPe intron probe is 286bp, used at 1.5:100 dilution. 
Forward primer: 5’- GAGGGGCAGATTATTTGTTAG -3’ 
Reverse primer: 5’- AATTAACCCTCACTAAAGGGAGAGCCAATAAATGAGAGG 
GAGTG -3’ 
 
D. eugracilis SxlPe intron probe is 492bp, used at 1.5:100 dilution. 
Forward primer: 5’- TGAGGATAGCGACTGTATGC -3’ 
Reverse primer: 5’-AATTAACCCTCAAAGGGAGAGAGATGATAGAGTTGTTGTC 
GG -3’ 
 
FISH (fluorescence in situ hybridization) 
Fluorescein-labeled D. persimilis intron probe and dig-labeled D. eugracilis intron probe 
were used at 1:100 dilution. Hybridization were performed at 65ºC overnight. Sheep anti-
digoxigenin (Roche, double check) and mouse anti-fluorescein (Jackson 
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ImmunoResearch, Inc) were incubated with embryos at 4ºC overnight as primary 
antibodies. Alexa Fluor 555 donkey anti-sheep antibody (Molecular probes) and Alexa 
Fluor 647 chicken anti-mouse antibody (Molecular probes) were used as secondary 
antibodies. Embryos were stained with DAPI and mounted in VECTASHIELD mounting 
media (Vector Laboratories) or Prolong Diamond antifade mountant (ThermoFisher 
Scientific). 
 
Confocal Imaging 
Embryos were imaged using Olympus FV1000 confocal microscope from Texas A&M 
Microscopy and Imaging Center. Images were obtained as Z stacks of 7 to 8 sections (with 
1.52micron intervals) using 20X oil objective lens. The FISH signals from the two 
channels were false colored as green and red. Z-stacks were projected into 2D images by 
combining the maximum intensity from each stack using Olympus FluoView Viewer 
Version 4.2. 
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APPENDIX A 
 
 
This appendix contains all the supplement tables and figures for Chapter III.  
 
Data tables of all the genetic tests performed on delPe-SxlTG 
In the following tables, numerical data represent percentage of female viability. 
Numerical data in parenthesis represent the number of viable females. 
 
 
Complete table (viability data) for Table 3.1 (Complementation of Sxlf9mutants by 
delPe-SxlTG) 
 
 
 
Crosses   w Sxlf9ct/Binsincy; +/+ ×  w Sxlf9 ct /Y; TG/+ 
 
 
 
 
 
 
 
 
Genotype SxlPe0.2kbSxlTG
SxlPe0.4kb
SxlTG
SxlPe0.8kb
SxlTG
SxlPe1.1kb
SxlTG
SxlPe1.4kb
SxlTG
SxlPe3.0kb
SxlTG
SxlPe3.7kb
SxlTG SxlTG
ΔPe
SxlTG!"#$%	!"#$%		 ; 	++ 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)!"#$% 	!"#$% 	 ; )*+ 0(0) 0(0) 92.4(171) 111.2(99) 98(147) 92.3(168) 140.3(94) 110.9(112) 0(0)!"#$%+,-./ 	; 	++ 100(110) 100(82) 100(185) 100(89) 100(150) 100(182) 100(67) 100(101) 100(125)!"#$%+,-./ ;	 )*+ 108.2(119) 108.5(89) 119.5(221) 104.5(93) 106.7(160) 119.2(217) 123.9(83) 107.9(109) 123.2(154)!"#$%	0 	 ; 	++ 100(107) 100(87) 100(175) 100(105) 100(154) 100(181) 100(78) 100(132) 100(140)!"#$%	0 ; 	 )*+ 95.3(102) 104.6(91) 126.3(221) 161.4(124) 107.8(166) 91.7(166) 115.4(90) 96.2(127) 98.6(138)+,-./0 	; 	++ 92.5(99) 44.8(39) 45.7(80) 32.4(34) 41.6(64) 32.6(59) 34.6(27) 36.4(48) 40.7(57)+,-./0 	; 	)*+ 77.6(83) 35.6(31) 61.1(107) 36.2(38) 39(60) 2.8(5) 9(7) 3.8(5) 6.4(9)
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Complete table (viability data) for Table 3.2 (Complementation of Sxlf9/Sxlf1 
mutants by delPe-Sxl-Eug-TG) 
 
 
 
Crosses  y w cm Sxlf1 ct/Binsincy; +/+ ×   w Sxlf9 ct /Y; TG/+ 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype SxlPe0.8kbSxlTG
SxlPe1.1kb
SxlTG
SxlPe1.4kb
SxlTG
SxlPe3.0kb
SxlTG
SxlPe3.7kb
SxlTG SxlTG
ΔPe
SxlTG!"#$%	!"#$'		 ; 	++ 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)!"#$% 	!"#$' 	 ; *++ 38.6(39) 74.1(83) 99.1(106) 104.2(99) 99.0(99) 114.6(55) 0(0)!"#$%,-./0 	; 	++ 100(101) 100(112) 100(107) 100(95) 100(100) 100(48) 100(84)!"#$%,-./0 ;	 *++ 106.9(108) 88.4(99) 90.6(97) 113.7(108) 100(100) 93.8(45) 66.7(56)!"#$'1 	; 	++ 100(112) 100(98) 100(99) 100(92) 100(93) 100(40) 100(61)!"#$'1 ; 	*++ 99.4(99) 87.8(86) 86.9(86) 94.6(87) 122.6(114) 110.0(44) 116.4(71),-./01 	; 	++ 58.0(65) 48.0(47) 43.4(43) 71.7(66) 65.6(61) 117.5(47) 108.2(66),-./01 	; 	*++ 48.2(54) 36.7(36) 34.3(34) 48.9(45) 34.4(32) 12.5(5) 108.2(66)
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Complete table (viability data) for Fig.3.4A (Complementation of Sxlf9 mutants by 
one or two copies of 0.2kbSxlPe-SxlTG and 0.4kbSxlPe-SxlTG) 
 
 
 
Crosses   w Sxlf9ct/Binsincy; TG/+ ×  w Sxlf9 ct /Y; TG/+ 
 
 
 
 
 
 
 
 
Genotype SxlPe0.2kbSxlTG
SxlPe0.4kb
SxlTG SxlTG!"#$%	!"#$%		 ; 	++ 0(0) 0(0) 0(0)!"#$% 	!"#$% 	 ; )*+ 0(0) 0(0) 102.3(88)!"#$% 	!"#$% 	 ; )*)* 0(0) 0(0) 104.6(47)!"#$%+,-./ 	; 	++ 100(67) 100(69) 100(43)!"#$%+,-./ ;	 )*+ 78.3(105) 113.8(157) 105.8(91)!"#$%+,-./ ;	 )*)* 59.7(40) 89.8(62) 111.6(48)!"#$%	0 	 ; 	++ 100(42) 100(83) 100(51)!"#$%	0 ; 	 )*+ 129.8(109) 104.8(174) 96.1(98)!"#$%	0 ; 	 )*)* 83.3(35) 72.3(60) 86.3(44)+,-./0 	; 	++ 100(24) 100(32) 100(210+,-./0 	; 	)*+ 122.9(59) 100(64) 116.7(49)+,-./0 	; 	)*)* 62.5(15) 43.8(17) 42.8(9)
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Complete table (viability data) for Fig. 3.5B (Complementation of Sxlf9 mutants by 
0.4kbSxlPe-SxlTG and 0.4kbgalKSxlPe-SxlTG) 
 
Crosses   w Sxlf9ct/Binsincy; +/+ ×  w Sxlf9 ct /Y; TG/+ 
 
Complete table (viability data) for Fig. 3.5C (Complementation of Sxlf9/Sxlf1 
mutants by 0.4kbSxlPe-SxlTG and 0.4kbgalKSxlPe-SxlTG) 
 
Crosses  y w cm Sxlf1 ct/Binsincy; +/+ ×   w Sxlf9 ct /Y; TG/+ 
Genotype SxlPe0.4kbSxlTG
SxlPe0.4kbgalK
SxlTG
SxlPe0.8kb
SxlTG SxlTG!"#$%	!"#$%		 ; 	++ 0(0) 0(0) 0(0) 0(0)!"#$% 	!"#$% 	 ; )*+ 0(0) 92.6(100) 102.9(142) 89.7(96)!"#$%+,-./ 	; 	++ 100(85) 100(108) 100(138) 100(107)!"#$%+,-./ ;	 )*+ 116.5(99) 97.2(105) 110.1(152) 90.6(97)!"#$%	0 	 ; 	++ 100(92) 100(109) 100(127) 100(98)!"#$%	0 ; 	 )*+ 104.3(96) 106.4(116) 115(146) 112.2(110)+,-./0 	; 	++ 26.1(24) 23.8(26) 26.8(34) 31.6(31)+,-./0 	; 	)*+ 20.6(19) 45.9(50) 51.2(65) 3.1(3)
Genotype SxlPe0.4kbSxlTG
SxlPe0.4kbgalK
SxlTG
SxlPe0.8kb
SxlTG SxlTG!"#$%	!"#$'		 ; 	++ 0(0) 0(0) 0(0) 0(0)!"#$% 	!"#$' 	 ; *++ 0(0) 28.9(28) 38.6(39) 114.6(55)!"#$%,-./0 	; 	++ 100(96) 100(97) 100(101) 100(48)!"#$%,-./0 ;	 *++ 109.4(105) 90.7(88) 106.9(108) 93.8(45)!"#$'1 	; 	++ 100(102) 100(103) 100(112) 100(40)!"#$'1 ; 	*++ 86.3(88) 108.7(112) 99.4(99) 110.0(44),-./01 	; 	++ 61.8(63) 66.0(68) 58.0(65) 117.5(47),-./01 	; 	*++ 48.0(49) 52.4(54) 48.2(54) 12.5(5)
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Complementation of Sxl7BO mutants by delPe-SxlTG 
 
Crosses  y pn w Sxl7BO/Binsincy; +/+ ×  y pn w Sxl7BO/Y; TG/+ 
 
Complementation of Sxlf1 mutants by delPe-SxlTG 
 
Crosses  y w cm Sxlf1 ct/Binsincy; +/+ ×  y w cm Sxlf1 ct /Y; TG/+ 
Genotype SxlPe0.2kbSxlTG
SxlPe0.4kb
SxlTG
SxlPe0.8kb
SxlTG
SxlPe1.1kb
SxlTG
SxlPe1.4kb
SxlTG
SxlPe3.0kb
SxlTG
SxlPe3.7kb
SxlTG SxlTG
ΔPe
SxlTG!"#$%&	!"#$%& 	;	++ 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)!"#$%&	!"#$%& ;	*++ 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 110.7(93) 0(0)	!"#$%&,-./0 	;	++ 100(105) 100(102) 100(80) 100(84) 100(94) 100(96) 100(93) 100(84) 100(88)	!"#$%&,-./0 ;	*++ 108.6(114) 107.8(110) 92.5(74) 110.7(93) 84(79) 75(72) 110.7(103) 103.6(87) 109.1(96)!"#$%&1 	;	++ 100(103) 100(134) 100(57) 100(102) 100(78) 100(112) 100(108) 100(60) 100(105)!"#$%&1 ; 	*++ 107.8(111) 90.3(121) 115.8(66) 110.8(113) 83.3(65) 100(112) 90.7(98) 105(63) 109.5(115),-./01 	;	++ 84.5(87) 86.6(116) 115.8(66) 61.8(63) 98.7(77) 57.1(64) 56.5(61) 70(42) 48.6(51),-./01 	; 	*++ 68.9(71) 68.7(92) 103.5(59) 61.8(63) 75.6(59) 42(47) 23.1(25) 85(51) 61.9(65)
Genotype SxlPe0.2kbSxlTG
SxlPe0.4kb
SxlTG
SxlPe0.8kb
SxlTG
SxlPe1.1kb
SxlTG
SxlPe1.4kb
SxlTG
SxlPe3.0kb
SxlTG
SxlPe3.7kb
SxlTG SxlTG
ΔPe
SxlTG!"#$%	!"#$%		 ;	++ 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)!"#$%	!"#$%	 	; )*+ 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 109.9(111) 0(0)!"#$%+,-./ 	; 	++ 100(67) 100(50) 100(108) 100(126) 100(148) 100(89) 100(60) 100(101) 100(105)!"#$%+,-./ ; 	)*+ 103.0(69) 128.0(64) 137(148) 130.9(165) 110.8(164) 167.4(149) 168.3(101) 130.7(132) 106.7(112)!"#$%	0 	 ;	++ 100(69) 100(61) 100(141) 100(126) 100(136) 100(112) 100(67) 100(119) 98(100)!"#$%	0 ;	)*+ 102.9(71) 78.7(48) 133.3(188) 126.2(159) 151.5(206) 113.4(127) 213.4(143) 127.7(152) 90.8(89)+,-./0 	; 	++ 75.4(52) 80.3(49) 53.2(75) 36.5(46) 83.8(114) 89.3(100) 28.4(19) 44.5(53) 66.3(65)+,-./0 	;	)*+ 69.6(48) 65.6(40) 97.9(138) 88.1(111) 87.5(119) 84.8(95) 140.3(94) 52.9(65) 74.5(73)
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Complementation of Sxlf1 mutants by delPe-Sxl-Eug-TG 
 
Crosses  y w cm Sxlf1 ct/Binsincy; +/+ ×  y w cm Sxlf1 ct /Y; TG/+ 
 
Complementation of Sxlf9 mutants by delPe-Sxl-Eug-TG 
 
Crosses   w Sxlf9ct/Binsincy; +/+ ×  w Sxlf9 ct /Y; TG/+ 
Genotype SxlPe0.4kbSxlTG
SxlPe0.8kb
SxlTG
SxlPe1.1kb
SxlTG
SxlPe1.4kb
SxlTG
SxlPe3.0kb
SxlTG
SxlPe3.7kb
SxlTG SxlTG
ΔPe
SxlTG!"#$%	!"#$%		 ;	++ 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)!"#$%	!"#$%	 	; )*+ 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 109.9(111) 0(0)!"#$%+,-./ 	; 	++ 100(72) 100(38) 100(43) 100(34) 100(115) 100(101) 100(101) 100(105)!"#$%+,-./ ; 	)*+ 127.8(92) 142.1(54) 148.8(64) 100(34) 80.4(143) 115.8(117) 130.7(132) 106.7(112)!"#$%	0 	 ;	++ 100(89) 100(65) 100(67) 100(28) 100(121) 100(85) 100(119) 98(100)!"#$%	0 ;	)*+ 96.6(86) 123.1(80) 94(63) 139.3(39) 129.8(157) 156.5(133) 127.7(152) 90.8(89)+,-./0 	; 	++ 60.7(54) 65.6(42) 74.6(50) 114(11) 54.5(66) 85.9(73) 44.5(53) 66.3(65)+,-./0 	;	)*+ 93.2(83) 83.1(54) 80.6(54) 75(21) 77.7(94) 83.5(71) 52.9(65) 74.5(73)
Genotype SxlPe0.4kbSxlTG
SxlPe0.8kb
SxlTG
SxlPe1.1kb
SxlTG
SxlPe1.4kb
SxlTG
SxlPe3.0kb
SxlTG
SxlPe3.7kb
SxlTG SxlTG
ΔPe
SxlTG!"#$%	!"#$%		 ; 	++ 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)!"#$% 	!"#$% 	 ; )*+ 0(0) 102.9(142) 104.8(109) 77.1(118) 118.9(132) 88.3(129) 110.9(112) 0(0)!"#$%+,-./ 	; 	++ 100(85) 100(138) 100(104) 100(153) 100(111) 100(146) 100(101) 100(125)!"#$%+,-./ ;	 )*+ 116.5(99) 110.1(152) 90.4(94) 103.4(122) 82.6(109) 102(149) 107.9(109) 123.2(154)!"#$%	0 	 ; 	++ 100(92) 100(127) 100(121) 100(123) 100(123) 100(128) 100(132) 100(140)!"#$%	0 ; 	 )*+ 104.3(96) 115(146) 88.4(107) 88.6(109) 98.4(121) 121.9(156) 96.2(127) 98.5(138)+,-./0 	; 	++ 26.1(24) 26.8(34) 36.4(44) 42.3(52) 36.6(45) 25(32) 36.4(48) 40.7(57)+,-./0 	; 	)*+ 20.6(19) 51.2(65) 53.7(65) 37.4(46) 9.7(12) 13.3(17) 3.8(5) 6.4(9)
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Complementation of Sxlf9/Sxlf1 mutants by delPe-Sxl-TG 
 
 
 
Crosses  y w cm Sxlf1 ct/Binsincy; +/+ ×   w Sxlf9 ct /Y; TG/+ 
 
 
 
 
 
In situ hybridization of SxlPe0.2kb and SxlPe0.4kb transgenic lines 
 
Surface views of embryos were shown in both 20X and 100X. 
 
 
 
Genotype SxlPe0.8kbSxlTG
SxlPe1.1kb
SxlTG
SxlPe1.4kb
SxlTG
SxlPe3.0kb
SxlTG
SxlPe3.7kb
SxlTG SxlTG
ΔPe
SxlTG!"#$%	!"#$'		 ; 	++ 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)!"#$% 	!"#$' 	 ; *++ 42.2(46) 87.3(89) 94.7(142) 85.6(119) 100(128) 114.6(55) 0(0)!"#$%,-./0 	; 	++ 100(109) 100(102) 100(150) 100(139) 100(128) 100(48) 100(84)!"#$%,-./0 ;	 *++ 108.3(118) 104.9(107) 79.3(119) 76.9(107) 91.3(104) 93.8(45) 66.7(56)!"#$'1 	; 	++ 100(102) 100(83) 100(121) 100(120) 100(133) 100(40) 100(61)!"#$'1 ; 	*++ 96.1(98) 114.5(95) 98.3(119) 94.2(113) 91.7(122) 110.0(44) 116.4(71),-./01 	; 	++ 74.5(76) 100(83) 73.6(89) 84.2(101) 76.7(102) 117.5(47) 108.2(66),-./01 	; 	*++ 86.3(88) 96.4(80) 78.5(95) 69.2(83) 55.6(74) 12.5(5) 108.2(66)
A
B Cycle 14 earlyCycle 13
SxlPe0.4kb-Sxl-Eug-TG
Sxl-Eug-TG
Genotype SxlPe0.2kbSxlTG
SxlPe0.4kb
SxlTG	"#$%&		"#$%&	; '() 0(0) 0(0)	"#$%&		"#$%&	; '('( 0(0) 0(0)
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All categories of SxlPe activity observed in cycle 13 females carrying delPe-Sxl-Eug-
TG  
 
 
 
Nuclear dots represent nascent SxlPe transcripts. Surface views of embryos were shown 
in both 20X and 100X. 100X pictures were taken at the center of the embryos. 
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All categories of SxlPe activity observed in early cycle 14 females carrying delPe-
Sxl-Eug-TG 
  
 
 
Nuclear dots represent nascent SxlPe transcripts. Surface views of embryos were shown 
in both 20X and 100X. 100X pictures were taken at the center of the embryos. 
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APPENDIX B 
 
 
 
This appendix contains all the supplement tables and figures for Chapter IV.  
 
 
 
Data tables of all the genetic tests performed on Sc/DaMSxlPe-SxlTG 
In the following tables, numerical data represent percentage of female viability. 
Numerical data in parenthesis represent the number of viable females. 
 
 
 
 
 
Complete table (viability data) for Table 4.2A (Complementation of Sxlf1mutants 
by Sc/DaMSxlPe-SxlTG) 
 
Crosses  y w cm Sxlf1 ct/Binsincy; +/+ ×  y w cm Sxlf1 ct /Y; TG/+ 
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Complete table (viability data) for Table 4.2B (Complementation of Sxl7BO mutants 
by Sc/DaMSxlPe-SxlTG) 
 
Crosses  y pn w Sxl7BO/Binsincy; +/+ ×  y pn w Sxl7BO/Y; TG/+ 
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Complementation of Sxlf9 mutants by Sc/DaMSxlPe-SxlTG 
 
Crosses  y w cm Sxlf1 ct/Binsincy; +/+ ×  y w cm Sxlf1 ct /Y; TG/+ 
 
 
 
 
 
 
 
 
 
  120 
 
 
 
 
 
Complete table (viability data) for Table 4.3A (Complementation of Sxlf1mutants 
by Sc/DaMSxlPe-SxlTG) 
 
Crosses  y w cm Sxlf1 ct/Binsincy; +/+ ×  y w cm Sxlf1 ct /Y; TG/+ 
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Complete table (viability data) for Table 4.3B (Complementation of Sxl7BO mutants 
by Sc/DaMSxlPe-SxlTG) 
 
Crosses  y pn w Sxl7BO/Binsincy; +/+ ×  y pn w Sxl7BO/Y; TG/+ 
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Sc/Da binding site mutant embryos categorized based on their level of SxlPe 
activity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Binding sites mutation
SxlPe activity
Total 
number of 
embryos 
counted
Wild-type 
activity 
(%)
Slightly affected 
activity and 
moderately 
affected activity 
(%)
Strongly 
affected 
activity 
(%)
Severely 
affected 
activity
(%)
No 
activity
(%)
Sc/Da 1- Cycle 12
Cycle 13
Cycle 14 early
36
54
15
48
3
52
46
46
15
33
26
Sc/Da 2- Cycle 12
Cycle 13
Cycle 14 early
20
11
10
33
44
22
2
56
48
54
18
40
46
Sc/Da 3- Cycle 12
Cycle 13
Cycle 14 early
2
25 25
10
42
90
56
50
10
36
28
Sc/Da 1- 2- Cycle 12
Cycle 13
Cycle 14 early
30
38
50
20
10
50
50
52
12
44
21
Sc/Da 1- 4- Cycle 12
Cycle 13
Cycle 14 early
22
47
22
7
56 44
56
44
9
27
45
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SxlPe activity observed in cycle 13 female embryos carrying Sc/Da binding site 
mutations 
 
 
 
 
 
Nuclear dots represent nascent SxlPe transcripts. Surface views of embryos were shown 
in both 20X and 100X. 100X pictures were taken at the center of the embryos. 
 
 
 
 
Strongly affected activity
Moderately affected activity
Slightly affected activity
Wild-type activity
Severely affected activity
Categories of SxlPe activity 20X 100X
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SxlPe activity observed in early cycle 14 female embryos carrying Sc/Da binding 
site mutations 
 
 
 
 
 
 
Nuclear dots represent nascent SxlPe transcripts. Surface views of embryos were shown 
in both 20X and 100X. 100X pictures were taken at the center of the embryos. 
 
 
 
 
 
 
 
 
Categories of SxlPe activity 20X 100X
Strongly affected activity
Moderately affected activity
Slightly affected activity
Wild-type activity
  125 
 
 
Data tables of all the genetic tests performed on DpnMSxlPe-SxlTG 
In the following tables, numerical data represent percentage of female viability. 
Numerical data in parenthesis represent the number of viable females. 
 
 
 
 
 
 
Complementation of Sxlf1mutants by DpnMSxlPe-SxlTG 
 
Crosses  y w cm Sxlf1 ct/Binsincy; +/+ ×  y w cm Sxlf1 ct /Y; TG/+ 
For Dpn 1-2-3-SxlPe-SxlTG, the crosses were set up as  y w cm Sxlf1 ct /Binsincy; 
TG/+ ×  y w cm Sxlf1 ct /Y; +/+.  
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Complementation of Sxl7BOmutants by DpnMSxlPe-SxlTG 
 
Crosses  y pn w Sxl7BO/Binsincy; +/+ ×  y pn w Sxl7BO/Y; TG/+ 
For Dpn 1-2-3-SxlPe-SxlTG, the crosses were set up as  y pn w Sxl7BO /Binsincy; 
TG/+ ×  y pn w Sxl7BO /Y; +/+.  
 
Complementation of Sxlf9mutants by DpnMSxlPe-SxlTG 
 
Crosses   w Sxlf9ct/Binsincy; +/+ ×  w Sxlf9 ct /Y; TG/+ 
For Dpn 1-2-3-SxlPe-SxlTG, the crosses were set up as  w Sxlf9ct / Binsincy; TG/+ ×        
 w Sxlf9ct /Y; +/+.  
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Lethality test in wildtype flies carrying one copy of DpnMSxlPe-SxlTG 
 
Crosses +/+; TG/+ × +/Y; +/+ 
 
 
 
 
Complete table (viability data) for Table 4.4A (Lethality test in wildtype flies 
carrying one and two copies of DpnMSxlPe-SxlTG) 
 
Crosses +/+; TG/+ × +/Y; TG/+ 
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Complete table (viability data) for Table 4.4B (Lethality test of Sxl7BO mutants 
carrying one/two copies of DpnMSxlPe-SxlTG) 
 
Crosses  y pn w Sxl7BO; TG/+ ×  y pn w Sxl7BO/Binsincy /Y; TG/+ 
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Data tables of the genetic tests performed on other binding site mutations  
In the following tables, numerical data represent percentage of female viability. 
Numerical data in parenthesis represent the number of viable females. 
 
 
 
 
 
 
Complementation of Sxlf1 mutants by other binding site mutations  
 
Crosses  y w cm Sxlf1 ct/Binsincy; +/+ ×  y w cm Sxlf1 ct /Y; TG/+ 
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Complementation of Sxl7BO mutants by other binding site mutations  
 
Crosses  y pn w Sxl7BO/Binsincy; +/+ ×  y pn w Sxl7BO/Y; TG/+ 
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Complementation of Sxlf9 mutants by other binding site mutations  
 
Crosses   w Sxlf9ct/Binsincy; +/+ ×  w Sxlf9 ct /Y; TG/+ 
 
